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1) List of Abbreviations 
 
2D  Two- dimensional 
3D  Three-dimensional 
BLM  Bleomycin 
BMP-7  Bone morphogenic protein-7 
BUD  Budesonide 
CCD  Charge-coupled device  
CD3  Cluster of differentiation 3 
Col1α1 Collagen type I, alpha 1 
Col1α2 Collagen type I, alpha 2 
Col3α1 Collagen type Ill, alpha 1 
CompA Compound A 
COPD  Chronic obstructive pulmonary disease  
CT  Cycle threshold 
CTGF  Connective tissue growth factor  
DCE  Dynamic contrast enhanced 
DMSO  Dimethyl sulfoxide 
ECM  Extracellular matrix 
EGF  Epidermal growth factor 
F4/80  EGF-like module containing mucin-like, hormone receptor-like sequence 1 
FAP  Fibroblast Activation Protein 
FOV  Field of view 
GE  Gradient echo 
GFR  Glomerular filtration rate 
H&E  Hematoxylin and eosin 
HA  Hyaluronic acid 
HGF  Hepatocyte growth factor  
HPLC/MS High performance liquid chromatography/mass spectrometry  
HPRT  Hypoxanthine-guanine phosphoribosyltransferase  
HYAL  Hyaluronidase 
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IBA-1  Ionized calcium-binding adapter molecule 1  
IN  Intra-nasal 
i.p.  Intra-Peritoneal 
IPF  Idiopathic pulmonary fibrosis 
IT  Intra-tracheal  
i.v.  Intra-venous 
LAR  Long acting release 
MCP   Monocyte chemotactic protein 
MIP   Macrophage inflammatory protein 
MMP12 Matrix metalloproteinase 12 
MRI  Magnetic resonance imaging 
NIRF  Near infra-red fluorescence imaging 
OA  Oropharyngeal aspiration 
PAS  Periodic acid-Schiff 
PBS  Phosphate buffered saline 
p.o.  Per os  
qRT-PCR  quantitative real-time polymerase chain reaction 
RF  Radio frequency 
RF  Renal fibrosis  
ROI  Region of interest 
SD  Sprague Dawley 
SE  Spin echo 
sem   standard error of the means 
SNR  Signal-to-noise ratio 
SPIO  Superparamagnetic iron oxide 
sstr  Somatostatin receptor 
T  Tesla 
TE  Echo time 
TGF-β  Transforming growth factor- β 
TIMP   Tissue inhibitor of metalloproteinases 
TR  Repetition time 
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TWR  Tracer washout rate 
U  Units 
UIP  Usual interstitial pneumonia  
UTE  Ultrashort echo time 
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2) Abstract 
Pulmonary fibrosis, an end result of various types of lung damage including interstitial 
pneumonia and respiratory bronchiolitis [1-3], is a lethal disease characterized by fibroblast 
proliferation and extracellular matrix (ECM) remodeling. About 20% of the cases are of 
unknown cause and are thus termed idiopathic pulmonary fibrosis (IPF). A comparable 
pathology can be observed in fibrotic kidneys. Chronic kidney diseases, as diabetic 
nephropathy, hypertensive nephropathy, or chronic glomerulonephritis, lead in most cases to 
renal fibrosis, a disease characterized by infiltration of inflammatory cells, fibroblast 
activation, glomerulosclerosis and tubulointerstitial fibrosis (for reviews see [4,5]) 
The work in this thesis concentrates on the validation of magnetic resonance imaging (MRI) 
as a non-invasive tool to follow longitudinally anatomical and functional changes related to 
lung and kidney injury induced in the corresponding small rodent models of fibrosis. 
Bleomycin, instilled into the lungs of mice or rats has been used to induce pulmonary fibrosis. 
Intra-venous injection of adriamycin induced nephropathy in rats. 
The bleomycin model was optimized introducing the oropharyngeal aspiration route for the 
antibiotic. Ultrashort echo time MRI was validated for the detection of lung lesions and tissue 
deposition in the pulmonary fibrosis model in rats and mice, while contrast enhanced 
gradient-echo MRI was validated to detect nephropathy and macrophage infiltration in the 
rat adriamycin model of renal fibrosis. In addition, two reference substances regarding the 
treatment of pulmonary fibrosis were found.  
In summary, the studies discussed in this thesis deliver contributions to three pillars of 
preclinical pharmaceutical research: the availability of appropriate animal models, the 
availability of readouts or parameters that quantitatively reflect disease evolution in those 
models, and the availability of reference compounds, known to interfere with the disease 
development.  
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3) Introduction 
3.1) Pulmonary and renal fibrosis – Overview and animal models 
Idiopathic pulmonary fibrosis 
In an official statement of the American Thoracic Society idiopathic pulmonary fibrosis (IPF) is 
defined as a “specific form of chronic, progressive, fibrosing interstitial pneumonia of 
unknown cause, occurring primarily in older adults, and limited to the lungs” [6]. For diagnosis 
of IPF the histopathological criteria of usual interstitial pneumonia (UIP) must be present, 
which include marked fibrosis/architectural distortion, with or without honeycombing in a 
predominantly subpleural/paraseptal distribution, presence of patchy involvement of lung 
parenchyma by fibrosis, presence of fibroblast foci, and absence of features against a 
diagnosis of UIP suggesting an alternate diagnosis (hyaline membranes, organizing 
pneumonia, granulomas, among others) [6-9]. Incidence and prevalence of IPF have only been 
studied in a few countries and were around 10 cases per 100’000 [8,10-16]. Whether they are 
influenced by geographic, ethnic, cultural, or racial factors is unknown. 
Pulmonary fibrosis in general, an end result of various types of lung damage including 
interstitial pneumonia and respiratory bronchiolitis [1-3] or with unknown cause (IPF), is a 
lethal disease characterized by fibroblast proliferation and extracellular matrix (ECM) 
remodeling.  A patchy alveolar wall fibrosis develops in patients with chronic obstructive 
pulmonary disease (COPD) whereas in chronic asthmatics, a fibrotic response occurs 
Figure 1: Lung fibrosis in small rodents A) Collagen staining on a left mouse lung lobe. Yellow areas represent collagen. B) Tissue remodeling 
in a fibrotic rat lung. Arrows point to thickened walls and tissue deposition. Fibrosis was induced by bleomycin. 
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predominantly in the lamina reticularis, leading to thickening of the basement membrane 
[17,18]. In both cases the ongoing inflammation-repair cycle leads to permanent structural 
changes in the airway wall (remodeling) of which fibrosis is a major constituent [19,20]. Up to 
50% of the pulmonary fibrosis cases are defined as IPF [21]. Although the pathway of 
remodeling during the fibrosis development is not yet completely understood, so far it is 
known that the lung structure is altered by the infiltration of inflammatory cells, thickening of 
the alveolar walls and deposition of collagen (Figure 1), elastin, and proteoglycans [22-27]. 
These changes in lung structure lead to an impairment of lung function. Increased lung tissue 
resistance and elastance, as well as decreased compliance have been shown in humans [2,15] 
and in small rodent pulmonary fibrosis models [23-25,28-31]. 
Bleomycin model for pulmonary fibrosis 
To date no effective treatment for pulmonary fibrosis is available. For the development of 
drugs against pulmonary fibrosis, the pharmaceutical research is dependent on animal models 
which are representative of the human disease. 
Bleomycin is an antibiotic with activity against gram-negative bacteria [32] that possesses 
chemotherapeutic properties and is highly efficient in some types of carcinomas. In spite of 
these therapeutic characteristics, bleomycin may produce a dose-dependent pulmonary 
fibrosis in a significant portion of patients [21]. Therefore, single [33-35] or multiple [36] 
instillation of bleomycin is commonly used to induce experimental pulmonary fibrosis in small 
rodents. The intra-tracheal (IT) route of administration has been used to deliver bleomycin 
into the lungs of rats and mice [27,36-38]. Additionally, the intra-nasal (IN) route has also been 
adopted in mice. Application of the antibiotic causes an acute inflammatory reaction and 
fibrotic changes that resemble human fibrotic lung disease both histologically and 
physiologically [22,39]. The availability of this animal model of pulmonary fibrosis provides the 
opportunity to investigate novel pharmacological approaches aiming to treat this crippling 
disease. 
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Renal Fibrosis 
Chronic kidney diseases, as diabetic nephropathy, hypertensive nephropathy, or chronic 
glomerulonephritis, lead in most cases to renal fibrosis, a disease characterized by infiltration 
of inflammatory cells, fibroblast activation, glomerulosclerosis and tubulointerstitial fibrosis 
(Figure 2; for reviews see [4,5]). The pathology of renal fibrosis shows several parallels to 
pulmonary fibrosis. In both cases deposition of ECM proteins leads to scarring of the organ, 
destruction of parenchyma, and a loss of organ function. The end-result of renal fibrosis is in 
most cases organ failure, which requires dialysis or organ transplantation [4,5]. A treatment 
against renal fibrosis is of high interest, but the development of anti-fibrotic drugs, as against 
renal fibrosis, is challenging. In the past years, research focused a.o. on targeting transforming 
growth factor- β (TGF-β), hepatocyte growth factor (HGF), and bone morphogenic protein-7 
(BMF-7) [40-44], but to date no drug against renal fibrosis is available. The lack of treatment 
and the limitation of diagnosis to 
biopsies (as for pulmonary fibrosis) 
mean heavy burden for the patients. As 
mentioned before, pharmaceutical 
research is dependent on animal models 
and in vivo readouts. In this work, the 
adriamycin model in rats has been used.  
Adriamycin induced nephropathy 
Adriamycin (doxorubicin, Pfizer) is 
licensed for the treatment of different 
cancers, such as breast, lung, and 
ovarian cancer. The medication works by 
binding to DNA in cells, altering the 
shape of the DNA and killing the cells. 
While adriamycin can kill healthy and 
cancerous cells, it has a greater effect on 
cancerous cells because they multiply 
more rapidly. Adriamycin is a well-
Figure 2: Periodic acid-Schiff (PAS) staining of renal sections at 
400x magnification. A) Healthy kidney without abnormalities. B) 
Arrows point to sclerotic tubuli in a fibrotic kidney. Renal fibrosis 
was induced by i.v. injection of adriamycin. 
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known inducer of renal injury in rodents, which mirrors that seen in human chronic kidney 
disease due to primary focal segmental glomerulosclerosis [45-47]. Adriamycin-induced 
nephropathy has enabled a greater understanding of the processes underlying the 
progression of chronic proteinuric renal disease [48,49]. The model is characterized by 
podocyte injury followed by glomerulosclerosis, tubulointerstitial inflammation and fibrosis 
(Figure 2). 
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3.2) Magnetic Resonance Imaging – Basic Principles and Sequences 
Magnetic Resonance Imaging (MRI) is a technique, mainly developed between 1970 and 1980 
by Paul Lauterbur and Peter Mansfield, which is able to visualize in vivo atomic nuclei, after 
their magnetization and induction of precession by radio frequency (RF) pulses, due to their 
differences in relaxation after the RF pulse.  
Basic Principles 
When a sample is placed in a constant 
magnetic field [for this work either a 4.7 
or a 7.0 Tesla (T) Biospec spectrometer 
(Bruker Medical Systems, Ettlingen, 
Germany) has been used], some of the 
atomic nuclei (mainly protons) owning a 
magnetic moment (due to spin) align 
with the magnetic field (Figure 3). This 
is the equilibrium situation. When an RF 
pulse is applied at the Larmor 
Figure 3: Schematic view of natural orientation of protons/spins (A) 
and their alignment with a magnetic field M(Z) in z-direction (B). 
Figure 4: Schematic view of the induction of precession by a 90° RF pulse followed by the longitudinal and transverse 
spin relaxation. The time needed for longitudinal and transverse relaxation is called T1 and T2, respectively. 
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frequency during approximately 1 ms or a fraction thereof, nuclei absorb the energy from the 
RF and are driven out of the equilibrium. They try to recover the alignment with the static 
magnetic field after the pulse has ended. The RF pulse can be applied with any angle and the 
following relaxation of the spin is dependent on its interaction with other spins (spin-spin 
relaxation characterized by the transverse relaxation time, T2) and its environment (spin-
lattice relaxation characterized by the longitudinal relaxation time, T1) (Figure 4). A certain 
time after the RF pulse (Echo time, TE), the radio frequency signal of the spins, induced by 
their precession, is detected by a receiver coil. In the simplest MR experiment, only one RF 
pulse is applied. If the experiment is repeated, for instance in order to improve the signal-to-
noise ratio (SNR) of the acquisition, then the interval between the RF pulses is called repetition 
time (TR). 
Since the Larmor frequency of a spin is directly proportional to the local magnetic field, B0, 
spatial information can be obtained by superimposing a gradient magnetic field onto the static 
magnetic field during data acquisition (only during a few ms). When a gradient is applied, then 
the resonance frequencies of the nuclei vary linearly along the direction of the applied 
gradient. By applying a gradient e.g. along the z direction simultaneously with a frequency 
selective RF pulse, a slice can be selected perpendicularly to the z direction. Spatial 
codification of the signals from the spins on the slice is then obtained by applying successively 
gradients that are perpendicular to each other and also to the slice gradient, e.g. along the x 
and y directions. These are called respectively the phase encoding and the readout gradients.  
With changing parameters as TE, TR, or flip angle of the RF pulse, the influence of tissues’ T1 
and T2 on the contrast of the acquired image may be shifted. With a rather short TR and TE, 
so called T1-weighed images are acquired, since only tissues with short T1 achieve longitudinal 
relaxation and deliver a strong signal with the next excitation. Using a long TE and TR, tissues 
with short T2 achieve transversal relaxation and lose their signal, while tissue with long T2 
appear bright on the image, which is called T2-weighted. If a long TR and short TE is chosen, 
the contrast is not built by differences in T1 or T2 but only by the amount of spins that deliver 
a signal and the image is proton-weighted. Due to constant inhomogeneity of the magnetic 
field, as for instance induced by tissue-air-interfaces, T2 of the involved tissues can be further 
reduced and is then called T2*. A good example for a tissue with T2*-effect is the lung -one of 
the organs in focus in the present thesis - where the interface between air and alveolar tissue 
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causes a very short T2*[50], which poses challenges when imaging the lung tissue 
(parenchyma). 
Spin echo sequence  
A 90° slice selective RF pulse is used for spin echo (SE) sequences, after which spins are 
dephasing with T2*. After half of TE, a second pulse with 180° is applied, let the spins switch 
their order and rephase after another half TE (Figure 5), which induces an echo. The advantage 
of this sequence is the elimination of T2*-effects due to the 180°-pulse, which enables the 
acquisition of T2-weighed images. The weak point is the long acquisition time, caused by the 
time-consuming second pulse, which makes the sequence susceptible to motion induced 
artifacts. This is particularly the case in the chest and abdominal region, since breathing of the 
animal may cause strong movement artifacts. Other approaches like gradient-echo and 
ultrashort TE (UTE) sequences are more useful for lung imaging. 
Ultra short echo time (UTE)  
In 1991 Bergin et al. described a sequence for the detection of lung parenchyma, aimed to 
reduce inconsistencies caused by motion of the scanned body [51-54]. The described 
projection reconstruction method enabled TE of less than 300 µs and visualization of lung 
parenchyma in spite of its very short T2*[51,52]. Such two-dimensional (2D) ultrashort echo 
time (UTE) sequences have been used for most of the studies described below and performed 
Figure 5: Schematic view of echo induction of a spin echo sequence: A second 180° RF pulse causes rephasing of the 
spins. 
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at 4.7 T (Figure 6A). With TE’s of 
the order of 600 µs signals 
induced by bleomycin could be 
readily detected and quantified. 
When moving to 7 T, because of 
even shorter T2* values, we 
realized that shorter TE’s would 
be necessary in order to be able 
to detect signals in the lung. 
Three-dimensional (3D) UTE sequences, where another phase-encoding gradient in z-direction 
was applied to detect signal of the whole field of view (FOV), increased the detectable signal 
at 7.0 T,  as TE’s of the order of 20 µs were feasible (Figure 6B).    
 
Gradient echo sequence 
Compared to SE sequences, no 180° pulse is needed to induce an echo for signal detection in 
gradient echo (GE) sequences. After excitation by the RF pulse and slice and phase encoding, 
follows the frequency-encoding process in two steps:  the frequency-encoding gradient (x) is 
applied first with negative polarity to induce dephasing and again with positive polarity to 
induce rephasing and consequently an echo (Figure 7). In this case, one speaks of gradient-
recalled echo formation. Compared to spin-echo, much shorter TR’s are possible and the 
Figure 7: Gradient echo: Dephasing and Rephasing are induced by a frequency gradient with negative and positive 
polarity, respectively. 
Figure 6: 2D and 3D UTE-MRI at 4.7 T and 7.0 T, respectively. Three-
dimensional acquisition facilitates imaging of lung parenchyma. 
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acquisition time can be reduced. Thus, GE sequences are less influenced by motion artifacts 
and are the sequence of choice when short acquisition times are needed. There are a few 
examples discussed in this work, where short acquisition times were needed and GE 
sequences have been applied. An imaging session with respiratory-triggered UTE MRI could 
last for more than an hour and would not allow an acceptable throughput and perfusion 
measurements of the kidney require the acquisition of images with a sub-second time 
resolution. For both cases GE sequences have been applied (For example see Figure 8).  
Contrast enhancement 
In some cases, especially for functional studies, the natural contrast of tissues and fluids is not 
sufficient and has to be enhanced by so called contrast agents. For instance, the investigation 
of kidney perfusion and renal clearance, discussed in Chapter 6.1 (“Adriamycin-Induced 
Nephropathy in Rats: Functional and Cellular Effects Characterized by MRI”) of this work, was 
Figure 8: GE-MRI : Signal decrease in blood vessels and kidney induced by SPIO particles. GE sequence allows a short 
acquisition time. Perfusion information can be derived from the relative signal change induced by the first passage of SPIO 
through the vascular system of the kidney. 
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possible due to the use of Endorem and Dotarem, respectively. The intravascular contrast 
agent, Endorem, contains superparamagnetic iron oxide (SPIO) nanoparticles with 
superparamagnetic properties that change the local magnetic field and thus impacts T1/T2*. 
A decrease of MRI-signal induced by SPIO particles to investigate kidney perfusion in mice is 
shown in Figure 8. The extravascular extracellular contrast agent, Dotarem (gadoteric acid, 
Gd-DOTA), has paramagnetic properties and decreases the T1 of protons.  
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3.3) MRI in pharmaceutical research 
Use of MRI in preclinical research 
Drug design and development is a time and resource consuming process. To reduce time effort 
and costs, substances and their in vivo effects have to be characterized as early as possible. 
MRI with its noninvasive character and its high spatial resolution offers the opportunity to gain 
anatomical and physiological information in vivo, which makes it an important tool for 
pharmaceutical research. Already during the early target identification and validation phase 
(Figure 9) MRI can for instance be used to identify the phenotype of genetically modified mice 
[55-58]. In later preclinical phases, during in vivo pharmacodynamic and safety studies in 
animal models, MRI delivers important information on anatomical or physiological changes 
induced by compound treatment [59]. In these phases, especially for animal model testing, 
MRI is most often used [57]. 
 
Figure 9: Schematic view of the drug development process. MRI plays an important role in four out of five steps of drug 
discovery: Phenotyping of genetically modified mice during target identification and validation, substance testing in 
animal disease models, monitoring of side effects during the safety and development phase, as well as during clinical trials 
in humans. 
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MRI and 3R 
In 1959 Russel and Burch introduced the 3R concept (Reduction, Refinement and 
Replacement) regarding humane treatment of laboratory animals [60]. The goal of scientists 
should be to minimize the number of animals (Reduction) in experiments, to reduce their 
suffering and pain (Refinement), and to support the substitution of animals whenever possible 
(Replacement). MRI turned out to have a high impact on the realization of the 3R-concept. 
Reduction 
The non-invasive character of MRI allows time course studies and delivers information for 
several time points with a lower number of animals than needed in terminal readouts. Since 
each animal can be used as its own control for MRI analyzes, either the statistical significance 
can be increased or less animals have to be used to reach certain significance. Further, imaging 
may facilitate go/no-go-decisions during drug development [57,61] and therewith avoid 
further unnecessary studies. 
Refinement 
Imaging enables a non-invasive recording of morphological and functional data which means 
a strong refinement, compared to invasive readouts as for instance biopsies. Since MRI allows 
monitoring a disease model over time, it facilitates the definition of a humane study 
termination date and reasonable study-abortion criteria, which prevents the animals from 
unnecessary pain and suffering. As mentioned before, MRI may increase the statistical 
significance of a study. Therefore, an animal model with a mild disease-course can often be 
chosen.  
Replacement 
The use of Imaging in clinical trials supports early go/no-go decisions in phase l/ll [57,62,63]. 
The optimization of the clinical phase may replace an animal experiment, which is at least 
indirectly supported by imaging techniques as MRI. 
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3.4) Thesis outline 
Three components are of fundamental importance in the context of preclinical 
pharmacological research in vivo aiming to develop new therapies (Figure 10): (i) the 
availability of appropriate animal models; (ii) the availability of readouts or parameters that 
quantitatively reflect disease evolution in those models; and (iii) the availability of reference 
compounds, known to interfere with the disease development. Preclinical research in the 
context of fibrosis is particularly challenging due to the lack of reference substances. 
Moreover, being a chronic condition, the search for therapies would highly benefit from the 
availability of non-invasive readouts.  
The work in this thesis concentrates on the validation of MRI as a non-invasive tool to follow 
longitudinally anatomical and functional changes related to lung and kidney injury induced in 
the corresponding small rodent models of fibrosis. Repetitive measurements open new 
avenues in testing compounds as the responses at several time points during the course of 
injury development and treatment can 
be compared. Specifically, studies at 
the chronic phase, when fibrosis is 
already established, become amenable. 
In an iterative process, it is shown how 
imaging can contribute to further 
optimization and refinement of the 
animal models. The studies presented 
in this thesis thus focus on three pillars: 
Method and readout validation, animal 
model optimization, and substance 
testing. 
 
 
 
 
 
Figure 10: Schematic view of important components for 
pharmaceutical research and drug development in preclinical 
phase (in vivo). 
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4) MRI as a readout for pulmonary fibrosis in mice and rats 
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Introduction 
Pulmonary fibrosis, characterized by fibroblast proliferation and extracellular matrix 
remodeling, is the end result of various types of lung damage including interstitial pneumonia 
and respiratory bronchiolitis [1-3].  A patchy alveolar wall fibrosis develops in patients with 
chronic obstructive pulmonary disease (COPD) whereas in chronic asthmatics, a fibrotic 
response occurs predominantly in the lamina reticularis, leading to thickening of the basement 
membrane [17,18]. In both cases the ongoing inflammation-repair cycle leads to permanent 
structural changes in the airway wall (remodeling) of which fibrosis is a major constituent 
[19,20]. However, up to 50% of the cases of pulmonary fibrosis are defined as idiopathic 
pulmonary fibrosis (IPF) [21].  
Bleomycin is an antibiotic with activity against gram-negative bacteria [32] that possesses 
chemotherapeutic properties and is highly efficient in some types of carcinomas. In spite of 
these therapeutic characteristics, bleomycin may produce a dose-dependent pulmonary 
fibrosis in a significant portion of patients [21]. Therefore, single [33-35] or multiple [36] 
instillation of bleomycin is commonly used to induce experimental pulmonary fibrosis in small 
rodents. Application of the antibiotic causes an acute inflammatory reaction and fibrotic 
changes that resemble human fibrotic lung disease both histologically and physiologically 
[22,39]. The availability of this animal model of pulmonary fibrosis provides the opportunity 
to investigate novel pharmacological approaches aiming to treat this crippling disease. 
The intra-tracheal (IT) route of administration has been used to deliver bleomycin into the 
lungs of rats and mice [27,36-38]. Additionally, the intra-nasal (IN) route has also been 
adopted in mice. Arguments for favoring the IN administration protocol in this species are the 
method’s simplicity and speed, and that it does not injure the trachea. A major disadvantage 
of the IN administration route is the inhomogeneous distribution of the liquid in the 
respiratory tract, which is dependent on different parameters as the volume of instilled fluid 
and the depth of anesthesia [64]. 
An alternative technique called oropharyngeal aspiration (OA) has been developed to 
administer substances into the lungs of mice. One of the first applications of this method can 
be found in a study by Foster et al., who used OA for the instillation of 99mTC-labelled sulfur 
colloid to measure mucociliary function in mice by scintigraphy [65]. Rao et al. used the 
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technique to administer fluorescent amine-modified polystyrene latex beads and beryllium 
oxide particles into the mouse lung. They found the technique to be simple and reproducible 
and the exposures of the lung to be highly correlated to the administered doses of substrates 
[66]. A comparison of IT to OA administration was performed by Lakatos et al. in a mouse 
model of silicosis [67]. Mice treated with crystalline silica administered via the OA route 
developed fibrosis with a more homogenous distribution all over the lung and with less 
variability. The OA method  has also been used in other studies as for instance a mouse model 
of chemical-induced asthma [68] or a murine model of diacetyl toxicity [69]. 
Recently we reported the use of MRI to non-invasively follow the course of lung injury induced 
by repeated IN administration of bleomycin to mice [70], or of single or repeated IT bleomycin 
administration to rats [27]. In the present work this model of lung fibrosis has been further 
refined by adopting the OA administration route for bleomycin. The responses in the lungs 
detected in vivo by MRI have been compared to histology, hydroxyproline determination and 
quantitative real-time polymerase chain reaction (qRT-PCR) analyses.  
Material and Methods 
Ethics Statement 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(license number BS-1989). 
Animals 
Seven- to 9-week-old C57BL/6 (n=35) or BALB/c (n=37) male mice or Sprague Dawley (SD) rats 
(n=10) (Elevage Janvier, Saint Berthevin, France) were used throughout the study. Animals 
were kept at an ambient temperature of 22 ± 2°C under a 12 h normal phase light-dark cycle 
and fed NAFAG® pellets (Nahr- und Futtermittel AG, Gossau, Switzerland). Drinking water and 
food were freely available. 
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Intra-nasal administration of bleomycin or saline 
Mice were lightly anesthetized with 
2.0% isoflurane (Abbott, Cham, 
Switzerland) delivered in a box and 
bleomycin hydrochloride (Teva, Basel, 
Switzerland), 0.25 mg/kg in 25 µl of 
saline (0.9%) or vehicle (25 µl of saline 
(0.9%)) was administered IN with a 
micropipette (12.5 µl per nostril). 
Animals were allowed to recover 
immediately afterwards. This 
procedure was performed six times 
consecutively, once daily. Bleomycin 
solution was prepared before the first 
administration and then stored, in 
aliquots, at 4°C for administration at 
the further time points. A similar 
administration protocol has been 
shown earlier to induce substantial 
and sustained pulmonary fibrosis in mice [70]. The bleomycin solution kept at 4°C was stable 
over 6 days as verified by high performance liquid chromatography/mass spectrometry 
(HPLC/MS) analyses (Figure 11), a result that is consistent with earlier studies demonstrating 
that bleomycin in solution at room temperature is stable for more than two weeks [71].  
Oropharyngeal aspiration of bleomycin or saline in mice 
Animals were lightly anesthetized with 2% isoflurane delivered in a box and bleomycin 
hydrochloride (0.1 or 0.25 mg/kg for C57BL/6 mice; 0.5 or 1 mg/kg for BALB/c mice) in 40 µl 
of saline (0.9%) or vehicle (40 µl of saline (0.9%)) was administered via OA using a 
micropipette. OA was performed as described by de Vooght et al. [68]. Mice were fixed on a 
surgery board, the tongue was pulled out with a forceps, and the liquid was placed onto the 
Figure 11: HPLC/MS spectra of bleomycin (0.075mg/mL) freshly 
prepared and after six days at 4°C acquired on an xxx instrument (xxx). 
An acquity HSS T3 1.8 µm 2.1x50mm column was used at 60°C; eluent 
A (water + 0.05% formic acid + 3.75 mM ammonium acetate) and 
eluent B (acetonitrile + 0.04% formic acid) were used with a gradient of 
5 to 98% B in 1.4 min and 1.0 mL/min flow. Bleomycin A2: 
C55H84N17O21S3+ with a mass of 1415.56 g/mol; bleomycin B2: 
C55H84N20O21S2 with a mass of 1425.52 g/mol.  
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distal part of the oropharynx while the nose was gently closed. As for the IN administration 
protocol, the procedure was performed six times consecutively, once daily.  
Oropharyngeal aspiration of bleomycin in rats 
Animals were lightly anesthetized with 3.5% isoflurane delivered in a box and bleomycin 
hydrochloride, 2mg/kg in 100 µl of saline (0.9%) was administered via OA with a micropipette 
using a similar procedure as described above for mice.  
Magnetic resonance imaging (MRI)  
During MRI signal acquisitions, animals were placed in supine position in a cradle made of 
Plexiglas. Body temperature was kept at 37±1°C using warm air. Following a short period of 
introduction in a box, anesthesia was maintained with 1.5% isoflurane for mice and 2% for 
rats in a mixture of O2/N2O (1:2), administered via a nose cone. All measurements were 
performed on spontaneously breathing animals; neither cardiac nor respiratory triggering was 
applied. As demonstrated earlier [70,72], averaging over several respiratory cycles suppressed 
artifacts caused by movements of the chest and the heart without the necessity of triggering 
the data acquisition. Measurements were carried out with a Biospec 47/40 spectrometer 
(Bruker Medical Systems, Ettlingen, Germany) operating at 4.7 T and equipped with an actively 
shielded gradient system capable of generating a gradient of 200 mT/m. The operational 
software of the scanner was Paravision (Bruker).  
An ultra-short echo time (UTE) sequence [73-75] with the following parameters was applied 
for the detection of bleomycin-induced lung injury in mice: repetition time 20.0 ms, echo time 
529 µs, 604 projections, 2 averages, band width 200 kHz, flip angle of the excitation pulse 25°, 
matrix size 192x192, slice thickness 1.4 mm and FOV 3.0 x 3.0 cm2. The total acquisition time 
was of 4.0 min for 10 consecutive axial slices covering the entire lung. In an initial assessment, 
different numbers of averages were tested: 1 average (2-min-acquisition-time), 2 averages (4-
min-acquisition-time), 4 averages (8-min-acquisition-time), and 8 averages (16-min-
acquisition-time). It was found that the acquisition with 2 averages was appropriate and then 
used throughout the study. A birdcage resonator of 32 mm diameter was used for excitation 
and detection. For rats an UTE sequence with the following parameters was used: repetition 
time 8.0 ms, echo time 528 µs, 604 projections, 5 averages, band width 200 kHz, flip angle of 
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the excitation pulse 25°, matrix size 192x192, slice thickness 2.0 mm and FOV 6.0 x 6.0 cm2. 
The total acquisition time was of 7.25 min for 18 consecutive transverse slices covering the 
entire lung. A birdcage resonator of 70 mm diameter was used for excitation and detection. 
MR image analysis 
At a given time point, the area of bleomycin-induced lesions was quantified on each image 
from the dataset covering the whole lung, using a semi-automatic segmentation procedure 
implemented in the IDL (Interactive Data Language Research Systems, Boulder, Colorado, 
USA) environment on a Linux system. Images were first low-pass-filtered with a Gaussian 
profile filter and then transformed into a set of four grey level classes using adaptive Lloyd-
Max histogram quantitation. The highest class in the transformed images was extracted 
interactively by a region grower, whose border was drawn manually on each slice to control 
the growing and limit it to areas within the lung (Figure 12). For each image, the area thus 
segmented by region growing 
corresponded to high intensity signals 
in the lung. The total volume of high 
intensity signals was then calculated 
by adding the areas obtained for each 
image from the dataset, and 
multiplying the summed value by the 
slice thickness. Segmentation 
parameters were the same for all 
analyzed images.  
Post-mortem analyses 
Animals were sacrificed with an overdose of thiopental (Pentothal®, Abbott; 250 mg/kg intra-
peritoneal (i.p.), 0.2 ml) immediately after an MRI acquisition. The trachea was immediately 
ligated to avoid collapse of the lung. Following the organ’s removal, the left lobe was used for 
histological analyses, while the right lobes were employed for hydroxyproline and qRT-PCR 
analyses.  
Figure 12: Details of segmentation procedure. For each slice, a border 
is drawn manually to limit the segmentation of high intensity signals 
to the lung. Images correspond to a rat at A) baseline and B) day 7 
after OA of bleomycin (2 mg/kg).  
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Histology 
Histological analysis was performed as 
described in more detail earlier [72]. 
Lung lobes were immersed in 10% 
neutral buffered formalin for 24 h. 
Following fixation, lungs were trimmed, 
and three transverse sections 
approximately 0.8 mm thick were cut 
through the left lung (superior, median, 
and caudal parts) to include the main 
bronchi as well as the pulmonary 
alveoli. Sections were then dehydrated 
through increasing graded series of 
ethylic alcohol and embedded in one 
block of paraffin wax. Three serial 
histological slices (3 µm) were obtained 
from each section and stained with 
picrosirius red for the identification of 
collagen fibers and newly synthesized 
collagen (Figure 13). Although 
polarized light is useful for the dating of fibrosis [76-82], in this work histological slices have 
been examined under bright field illumination to detect and quantify collagen. The 
quantification of collagen in picrosirius stained slices using bright field has been described 
elsewhere [83-89].  For each animal, a mean value was derived from the analysis of nine 
histological slices. 
Collagen was quantified using the program "Histolab" (Microvision Instruments, Evry, France). 
Picrosirius-stained slides were examined with a light microscope (Eclipse E600, Nikon, Egg, 
Switzerland) connected to a charge-coupled device (CCD) progressive scan video color camera 
(XCD-U100 CR, Sony, Tokyo, Japan). The whole surface of three slices of the left lung was 
captured at x10 magnification. The color corresponding to picrosirius was extracted by 
threshold setting and the area corresponding to picrosirius staining calculated. The 
Figure 13: Picrosirius-stained histological slices of C57BL/6 mice 
observed at bright-field (left column) and at polarization (right 
column). The high intensity areas in the polarized view, 
corresponding to collagen, coincide well with the red areas in the 
bright-field view. In this work, collagen has been quantified by 
examining histological slices at bright-field. A) Saline-challenged 
mouse (OA administration). B) IN administration of bleomycin 
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percentage of picrosirius to the total lung surface analyzed was calculated for each animal. 
Results were shown as picrosirius factors, expressing the collagen content in the lungs of 
bleomycin-challenged animals relative to the mean collagen content in the lungs of saline-
treated animals.  
Determination of hydroxyproline in lung tissue samples 
Lung tissue samples were weighed, dried in an oven at 90°C overnight, and the weight was 
recorded again. Dry tissues were then boiled in 0.5 mL of 6 M HCl at 120°C overnight (8-16 h) 
in Pyrex tubes with heat- and acid-resistant screw-on caps (article TES-830-70G; Fisher 
Scientific, Wohlen, Switzerland). After cooling down and adding 5 µL of phenolphthalein (1%), 
the samples were neutralized with NaOH 10 M (Sigma N°S-5881) and 6 M HCl. Black 
precipitate and brown color was removed by adding 100 µL of carbon suspension [10 mg/mL 
activated charcoal (article C4386; Sigma-Aldrich, Buchs, Switzerland) in water], centrifugation, 
and filtration. Five microliters of standard or hydrolyzed sample were pipetted in triplicate 
onto a 96 well plate, and 5 µL citrate acetate buffer (5% citric acid, 7.2% sodium acetate, 3.4% 
sodium hydroxide, 1.2% glacial acetic acid, distilled water) was added to each well, as well as 
100 µL of freshly prepared chloramine-T solution (14.1mg chloramine-T, 0.1mL n-propanol, 
0.1mL distilled water, 0.8mL citrate acetate buffer). The samples were then incubated at room 
temperature for 20 minutes. After adding 100 µL of Ehrlich’s reagent (2.5 g of 4-
(dimethylamino)benzaldehyde, 9.3 mL of n-propanol, and 3.9 mL of 70% perchloric acid), the 
wells were incubated for 20 minutes at 65°C. After cooling down, the samples were measured 
at 550 nm on a spectrophotometer (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, 
USA) and a standard curve from 5 to 100 mg hydroxyproline in water was created. Data were 
expressed as µg/right lung lobe. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Removed lung tissue was stabilized in liquid nitrogen and stored at -80°C until use. For RNA 
purification, samples were transferred to a 2 ml Eppendorf tube with 1000 µl of RLT buffer 
(Qiagen, Hombrechtikon, Switzerland; #79216) and β-mercaptoethanol (Sigma-Aldrich; 
#M3148) and one stainless bead (Qiagen, #69989). Samples were homogenized (Qiagen Tissue 
Lyser, #85300) in two to three 1-min runs at 30 rotations/s each, with 1 min on ice between 
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the runs. After centrifugation for 3 min at 13 000 rpm, 4°C, 300 µl of the resulting supernatant 
were processed on the Rneasy Mini Kit (Qiagen, #74106) with a DNAse digestion step (Qiagen, 
#79254) following the manufacturer’s protocol. Resulting total RNAs were quantified on a 
NanoDropTM system (NanoDrop Technologies Inc., Wilmington, DE, USA) and 1 µg was 
reverse-transcribed using the high capacity cDNA RT kit (Applied Biosystems, Zug, Switzerland; 
#4368813). 
Expression of the different genes of interest was evaluated by RT- PCR using the ABI Prism 
7900HT system (Applied Biosystems). Briefly, 10 ng/µl equivalent RNA per well was distributed 
in a 384 well plates (Applied Biosystems, #4326270), with 5 µl of the Taqman Universal 
Mastermix 2X kit (Applied Biosystems, #4324020) and 0.5 µl of 20X Assay-on-demand mix 
Taqman probe (Applied Biosystem, #4331182). The probes used were Mm00801666_g1 
(Collagen type I, alpha 1; Col1α1), Mm00802529_m1 (epidermal growth factor-like module 
containing mucin-like, hormone receptor-like sequence 1, F4/80), and Mm00500554_m1 
(matrix metalloproteinase 12; MMP12). Expression for each sample was normalized to 
Hypoxanthine-guanine phosphoribosyltransferase (HPRT, probe Mm03024075 m1) and 
compared to the vehicle-treated group, using the 2-∆∆CT formula (2-(∆CT1 - ∆CT2)), where ∆CT1 is 
the averaged cycle threshold (CT) value of a sample, normalized to HPRT and ∆CT2 is the 
average of ∆CT in the control group (vehicle group), also normalized to the housekeeping 
gene, resulting in the relative fold induction. The expression of HPRT was the same in all 
analyzed groups. 
Near-infrared-fluorescence (NIRF) imaging for distribution analyses 
For comparison of the administration routes, in a separate set of experiments isoflurane-
anesthetized mice received a solution containing the fluorescent dye Cy5.5 either IN (25 µL; 
12.5 µL per nostril) or OA (25 µL). Animals were allowed to recover from anesthesia 
immediately after solution administration. However, they were sacrificed 60 min later with an 
overdose of thiopental (250 mg/kg i.p, 0.2 mL). The trachea was immediately ligated to avoid 
collapse of the lungs, which were harvested from the body. NIRF imaging was performed on 
the isolated lungs using a Photon Imager (Biospace Lab, Paris, France). For fluorescence 
excitation, a Xenon lamp at 660 nm was used. The fluorescent light emitted from the sample 
was detected by a charge-coupled device camera, equipped with a focusing lens system. The 
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matrix size of the images was 532 x 532 pixels. A hard filter was used for detection wavelength 
selection (700 nm).  
 
Statistics 
For statistical analysis the software SigmaPlot™ (Systat Software Inc., San Jose, CA, USA) has 
been used. One-way ANOVA and Bonferroni tests have been performed for endpoint readouts 
while one- or two-way repeated measures ANOVA with Bonferroni tests have been used for 
readouts with multiple measurements. The following abbreviations were used for the 
indication of significance: */#: 0.01<p<0.05; **/##: 0.001≤ p ≤ 0.01 ***/ ###: p< 0.001. 
 
 
 
 
 
Figure 14: Detection of bleomycin-induced lung injury by UTE-MRI in BALB/c mice. A) Measurements (4-min-acquisition-
time) on comparable slices before and at different time points (5, 9, and 23 days) after OA of 6 x 1.0 mg/kg bleomycin. 
Arrows point to bleomycin-induced lung injury. B) Comparison of UTE acquisitions with different numbers of averages 
in a bleomycin-treated animal. The volumes of signals in the lungs evaluated from these images were comparable for all 
acquisition conditions: 1 average (285.4 µL), 2 averages (281.7 µL), 4 averages (282.6 µL), 8 averages (280.4 µL). White 
arrows point to bleomycin induced lung injury. 
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Results 
Detection of bleomycin-induced lung injury in mice by optimized UTE-MRI with short 
acquisition time 
Due to a reduction of the echo time and a decrease in the number of averages, the acquisition 
time for MRI of mice lungs could be strongly shortened as compared to previous work [70,72]. 
Only four minutes were needed to generate images covering the whole lung of a mouse with 
ten slices, each averaged out of 2 single acquisitions (Figure 14A). The optimized acquisition 
was compared to longer acquisitions comprising 4 or 8 averages and resulting in data 
collection times of 8 and 16 minutes, respectively. Since the amount of
Figure 15: Comparison of OA to IN administration of bleomycin (6x0.25 mg/kg) in C57BL/6 mice (n=8 per group) by in vivo 
MRI and post-mortem analyses. All data are shown as means ± STDEV. A) Relative body weight and time point of death during 
the study. Animals have been sacrificed directly after their last measurements. Five out of eight mice receiving OA of 
bleomycin had to be sacrificed prematurely due to excessive bodyweight loss (A).  B) Total volume of MRI signals in the lung 
(µL). The signal at baseline contains contributions from vessels, whereas signals following bleomycin reflect additionally the 
injury inflicted by the antibiotic. C) Post-mortem determination of hydroxyproline in right lung lobes (day 37). D) Amount of 
collagen detected by histology of picrosirius in left lung lobes (day 37). Results are expressed as collagen content relative to 
mean collagen content in the lungs of saline-treated mice (picrosirius factor).    
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detected lung signal, in healthy as well as in bleomycin-treated animals, was similar for all 
tested protocols (Figure 14B), the shorter acquisition, allowing a higher throughput and a 
strong reduction of narcosis time, was preferred.  
OA of bleomycin led to increased induction of lung fibrosis in C57BL/6 mice compared to IN 
administration  
The volume of signals induced by repeated IN bleomycin dosing (6x0.25 mg/kg) as described 
in Babin et al. [25] and detected by MRI never exceeded 120 µL, for different experimenters 
and studies performed in C57BL/6 mice. The maximum initial weight loss was of 15%. When 
the dose of bleomycin was doubled, namely to 6x0.5 mg/kg IN, a higher response was 
obtained (approximately 150 µL), but 40% of the animals had to be sacrificed prematurely due 
to weight loss in excess of 20%. Taken together, these preliminary data suggested that 6x0.25 
mg/kg would be the best compromise for routine studies involving IN dosing of bleomycin, 
since fibrotic responses would be induced with low initial weight loss as shown earlier [25]. 
The main drawback of the IN dosing was that fibrotic lesions, despite being elicited in different 
Figure 16: Histology of picrosirius stained lung slices from C57BL/6 mice. Collagen (green) visualized by picrosirius staining 
in three slices of the left lung lobe (upper row). Magnified views (x200) of a portion of the corresponding histological 
slices are shown in the bottom row. A) Stained collagen content in saline treated mouse lung 37 days after administration. 
B) Stained collagen content in a mouse lung 37 days after last IN bleomycin administration (0.25 mg/kg on six consecutive 
days). C) Collagen content in a mouse lung 37 days after last OA of bleomycin (0.25 mg/kg on six consecutive days). 
Compared to the IN administration, the amount of picrosirius was six times higher when bleomycin was oropharyngeally 
aspirated and the distribution of picrosirus staining was more homogeneous. 
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lung lobes, appeared predominantly around the largest superior airways [25]. We thus aimed 
at verifying whether another route, namely OA, might lead to a more homogeneous 
distribution of fibrotic lesions throughout the lungs. As a first step, the same dose of bleomycin 
optimized for the IN studies, namely 6x0.25 mg/kg, has been used.  
C57BL/6 mice were treated on six consecutive days with saline or bleomycin (0.25 mg/kg) by 
either the IN or OA route. Whereas mice dosed with bleomycin IN had initial weight loss within 
10% of the body weight, five out of eight animals that received bleomycin OA had to be 
sacrificed prematurely because of excessive weight loss (≥ 20% of the initial body weight) 
(Figure 15A). MRI baseline measurements before the first administration of bleomycin 
allowed the use of each animal as its own control. Further MRI measurements were 
performed on several time points after last bleomycin administration. The course of MRI-
detected lung injury is shown in Figure 15B. Compared to the IN route, OA administration of 
bleomycin led to significantly higher responses in the lungs as evidenced by MRI from a very 
early (day 2 after last bleomycin administration) to a late time point (day 37 after last 
bleomycin administration) (Figure 15B). These findings were confirmed by post-mortem 
analysis of the lungs (37 days after last bleomycin administration).  Determination of 
hydroxyproline in the right lung lobe (Figure 15C) showed a significantly higher amount of 
hydroxyproline in lungs from mice that had received bleomycin via the OA than the IN route 
or the control group (Saline). The amount of hydroxyproline in the lungs of IN-treated mice 
differed only slightly from the saline group.  The amount of collagen in the left lung lobe was 
quantified by picrosirius staining in histological samples. The amount of collagen in the lungs 
of mice that had received bleomycin via OA was significantly higher than in all other groups 
(Figure 15D). There was no difference detectable between IN-treated animals and the control 
group. Additionally, the distribution of collagen after OA of bleomycin was more homogenous 
than after IN administration (Figure 16). For the OA route, fibrotic areas appeared all over the 
lung lobe (Figure 16C), while for the IN route, when compared to saline (Figure 16A), fibrotic 
lesions appeared mainly around the biggest airways (Figure 16B). No edema or emphysema 
has been observed by histology for either administration route. However, parenchymal 
infiltrate was more marked after OA of bleomycin than following IN administration of the 
antibiotic.  
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For comparison, the distribution of Cy5.5 for both administration routes has been studied on 
isolated lungs from a separate cohort of animals using NIRF imaging.  Sixty minutes after OA 
of the dye, a homogenous distribution of the fluorescence signal all over the lung was 
observed. After IN administration of the dye, at the same time point, the fluorescence signal 
appeared mainly in the upper part of the lung and the trachea (Figure 17).  
A known negative side effect of bleomycin-induced lung fibrosis in small rodents is a 
prominent loss of body weight. After OA of bleomycin (6 x 0.25 mg/kg), not only the amount 
of induced lung fibrosis was higher than for IN administration, but also the body weight loss 
(Figure 15A). For ethical reasons, five out of eight mice had to be sacrificed due to excessive 
weight loss (∼20% of the initial body weight). Thus, for the OA of bleomycin a dose reduction 
was required. While the initial weight loss was tolerable (<20%) (Figure 18A), an adequate 
response has been obtained with six times 0.1 mg/kg OA of bleomycin (Figure 18B-D).  
Dose adaptation of OA administered bleomycin in BALB/c mice 
The motivation to analyze the effects of OA of bleomycin in BALB/c mice was the fact that 
many transgenic models have a BALB/c background. Former studies have shown that a much 
higher dose of bleomycin is needed to induce an amount of lung fibrosis in BALB/c mice that 
is comparable to the response in C57BL/6 mice [70,90,91]. Thus, an up to ten times higher 
dose of bleomycin was expected to induce an adequate amount of lung fibrosis in BALB/c mice 
when using the OA method. Three different doses of bleomycin were tested in groups of eight 
animals and compared to saline-treated mice. The induced lung injury was detected by UTE-
MRI while picrosirius staining as well as determination of hydroxyproline and RT-PCR were 
Figure 17: Ventral NIRF images of the lungs from two mice 60 min after instillation of the dye Cy5.5 (0.1mg/mL) either 
via the IN route (A) or via OA (B). Yellow arrows point to the trachea. 
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performed post-mortem. Compared to baseline, lung injury detected by UTE-MRI was 
significantly increased in animals treated with either 0.5 or 1.0 mg/kg bleomycin on six 
consecutive days (Figure 19A). Mice that received bleomycin that was divided between only 
three days (3 x 1.0 mg/kg, every second day) demonstrated a significant increase of MRI lung 
signal during the initial phase only (up to nine days after last administration). A treatment with 
1.0 mg/kg on six consecutive days induced the significantly highest volume of lung injury in 
the four compared groups as evidenced by MRI and led to a tolerable loss of bodyweight (≤15 
%; data not shown). Regarding post-mortem analyses (23 days after last 
Figure 18: Detection of bleomycin-induced lung injury in C57BL/6 mice by UTE-MRI, picrosirius staining, and 
hydroxyproline determination. Animals were treated with 0.1 mg/kg bleomycin (n=9) or vehicle (n=5) on six consecutive 
days via OA. Data are shown as means ± STDEV. A) Relative body weight during the course of the experiment. The 
statistical significance values ***p<0.001 represent comparisons between saline and bleomycin-treated mice, at each 
time point. B) Total volume of MRI signals in the lung (µL). The signal at baseline contains contributions from vessels, 
whereas signals following bleomycin administration reflect additionally the injury induced by the antibiotic. The 
statistical significance values ***p<0.001 indicate comparison to baseline. C) Post-mortem determination of 
hydroxyproline in right lung lobes D) Picrosirius factor expressing the amount of collagen relative to the mean collagen 
content assessed in the lungs of saline-treated mice. The statistical significance value ***p<0.001 means comparison to 
saline treatment.  
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Figure 19: Dose adaptation of bleomycin to OA route and comparison of different bleomycin doses in BALB/c mice by 
UTE-MRI and post-mortem analyses (n=8 mice for each group except n=4 mice for histological analysis).  Data are shown 
as means±STDEV. One-way ANOVA (Two-Way repeated measures ANOVA for MRI-results) with Bonferroni tests was 
used for statistical analysis. A) Total volume of MRI signals detected in the lung by UTE-MRI The signal at baseline 
contains contributions from vessels, whereas signals following bleomycin administration reflect additionally the injury 
induced by the antibiotic. B) Collagen content in left lung lobes detected by picrosirius staining. The picrosirius factor 
expresses the amount of collagen relative to the mean collagen content in the lungs of saline-treated mice. B) Post-
mortem determination of hydroxyproline in right lung lobes (day 23); Data are shown as Mean ± STDEV of µg 
hydroxyproline per right lung. D-F) mRNA expression level of Col1α1, F4/80, and MMP12 compared to expression of 
HPRT. Data shown as means±STDEV of fold induction compared to control group. 
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bleomycin administration), only a sixfold administration of 1.0 mg/kg bleomycin induced an 
amount of lung fibrosis that led to a significant higher amount of collagen as detected by 
picrosirius staining (Figure 19B), hydroxyproline (Figure 19C), and Col1α1 gene expression  
(Figure 19D). The expression of MMP12 and F4/80, both markers for the presence of tissue 
macrophages [92-96], was significantly increased after a sixfold administration of 1.0 mg/kg 
bleomycin (Figure 19E-F).  Neither edema nor emphysema has been observed histologically. 
Administration of 6 x 0.5 and 3 x 1.0 mg/kg bleomycin led to moderate, 6 x 1.0 mg/kg 
bleomycin to marked parenchymal cellular infiltration. The correlations between MRI, and all 
other readouts (picrosirius, hydroxyproline, and gene expression of col1α1, F4/80 and 
MMP12; Table 1) were significant (p at least 0.005). The strongest correlation (R = 0.90, 
p<0.00001) was found between the volume of MRI lung signal and the amount of collagen 
(picrosirius staining).  
 
OA administration in rats 
Currently, IT is the most often 
used route to apply substances 
into rat lungs. It is a well-
established method and may still 
be the technique of choice for 
single dosing, but especially for 
multiple dosing there might be a 
preference for a less invasive 
administration route as for instance OA. Since there are not many reports available that 
describe the use of OA in rats, the feasibility of this administration route has been first tested 
in a single animal. One hundred microliters of saline were administered via OA, as described 
before. The liquid was rapidly aspired and no interruption of breathing, which is a common 
complication during IT administration, occurred. After a single dose of bleomycin (2 mg/kg) 
via OA, the development of lung injury was detected by UTE-MRI at different time points. 
Figure 20A shows a significant increase of MRI lung signal already seven days after 
administration that stayed constant until 21 days after bleomycin administration. A 
Correlation between MRI and R P 
Picrosirius 0.90 < 0.00001 
F4/80 gene expression 0.68 < 0.0001 
MMP12 gene expression 0.60 < 0.001 
Col1α1 gene expression 0.60 < 0.001 
Hydroxyproline 0.48 0.005 
Table 1: Correlations between MRI and all other readouts on day 23 analyzed in the 
present study for detection of bleomycin-induced lung fibrosis in BALB/c mice 
(n=32; except for Picrosirius n= 16): total MRI signal volume, picrosirius staining, 
hydroxyproline, and gene expression of Col1α1, F4/80 and MMP12. Saline-treated 
BALB/c animals (n=8, n=4 for picrosirius) were used as controls.  
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homogenous collagen accumulation all over the lung with comparable intensity was detected 
by picrosirius staining in the left lung lobes (Figure 20C). 
 
Discussion 
Despite substantial research during the last years, currently no efficacious treatment exists for 
lung fibrosis.  The availability of a robust animal model allowing reliable predictions is 
important for the development of therapeutics against lung fibrosis. Fibrosis can be modeled 
in mice by the instillation of bleomycin into the lung [39,97]. Having access to non-invasive 
imaging is an advantage in the context of therapeutic treatment analysis, as randomization 
before treatment is feasible and the effect of a therapy on each single animal can be followed 
longitudinally. This is especially important in view of the variability of the responses induced 
by bleomycin. For instance, the bleomycin-induced injury can be quantified at a certain time 
point, just before beginning of treatment. The lung injury quantified non-invasively would 
then serve as baseline, immediately prior to treatment initiation. Alternatively, the responses 
induced by bleomycin and quantified by MRI can be used to randomize the treatment groups, 
in order to have similar mean values at the beginning of treatment across the different groups 
of animals.  
Figure 20: Oropharyngeal aspiration of 2 mg/kg bleomycin or of saline in Sprague Dawley rats (n=5 per group); A) Volumes of 
signals (means±STDEV) detected by UTE-MRI in the lungs of rats before and after bleomycin; Two-way repeated measures 
ANOVA with Bonferroni tests was performed. The statistical significance values ***p<0.001, **p<0.01 indicate comparison to 
baseline as well as comparison to Saline group. B) Signals at baseline contain contributions from vessel (white arrow in upper 
panel), whereas signals following bleomycin administration reflect additionally the injury induced by the antibiotic (yellow 
arrows in lower panel).  C) Histological analysis of the left lung lobes. Yellow areas are representing collagen, stained by 
picrosirius; neither emphysema nor edema was observed. D) Magnified view (x200) of one of the histological slices 
demonstrating widespread fibrosis as evidenced by picrosirius staining. 
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Induction of lung fibrosis by IN or IT administered bleomycin has been used to investigate the 
effect of potential therapeutics or the influence of genes on the development of lung fibrosis 
for target finding [98,99]. Since, especially in mice, IT administration is difficult to perform and 
IN administration might lead to inhomogeneous responses, because of its dependence on 
different parameters as depth of anesthesia or animal position [64], it seemed to be 
appropriate to investigate the potential of the OA technique for the described model. 
In the present work we demonstrated that the OA administration route offers a possibility to 
further optimize the murine bleomycin model. Intra-nasal administration and OA of bleomycin 
were compared in C57BL/6 mice regarding the amount (detected by UTE-MRI, histology, and 
hydroxyproline determination) and the distribution of induced lung injury. The volumes of 
administered fluid were chosen based on earlier work [64,65,67]. Using autoradiography 
Southam et al. [64]have shown that IN administration of 25 µl of fluid to mice leads to a similar 
uptake in the lung than 40 µl. Conversely, IN administration of lower volumes, e.g. 5 µl, leads 
to a preferential uptake in the brain. In our hands, we verified that it was easier to administer 
a volume of 25 µl than of 40 µl, as the latter volume significantly favored the formation of 
bubbles, resulting in extravasation of fluid out of the nasal cavity. On the other hand, using 
scintigraphy Foster et al. [20] demonstrated that OA of 50 µl of fluid led to a significantly better 
uptake in the lungs than 25 µl. We followed the paper of Lakatos et al. [22] and adopted 40 µl 
for OA delivery. Bleomycin administration via the OA route induced significantly higher 
amounts of lung injury, detected by MRI in vivo and identified as fibrosis by histology, as 
compared to IN administration. One explanation for this observation might be the obviation 
of swallowing due to pulling out the tongue during the OA, whereas the animals are, 
theoretically, still able to swallow during IN administration. A second explanation is proposed 
by the study of Southam et al., who investigated the distribution of IN administered 99mTc-
labelled sulfide-colloid into different tissues [64]. When 25µL of 99mTc-labelled sulfide-colloid 
was administered IN, only 40 - 50 % reached the lung. The rest of the substance could be found 
in the brain (about 40%) and stomach (5-10%). According to our knowledge, no such study has 
been performed for the OA route but it might be suggested that, during OA of liquids, less 
material reaches the brain since the substance does not directly pass the nasal cavity with its 
access to the brain. Thus, the main part of oropharyngeally aspirated liquid should reach the 
lung. The more pronounced response induced by the OA of bleomycin allowed a significant 
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dose reduction from a total of 1.5 mg/kg to 0.6 mg/kg in C57BL/6 mice. This means a model 
refinement not only due the dose reduction of bleomycin but also because of the 
accompanying less pronounced body weight loss. Of note, the response induced by IN 
administration of bleomycin here was lower than that attained earlier for the same model 
[70]. A possible explanation could be the different suppliers of bleomycin in both studies. 
The dose of bleomycin in BALB/c mice could be successfully adapted to OA. A six fold dosing 
of 1.0 mg/kg bleomycin induced an adequate increase of MRI lung signal which is strongly 
correlating with lung collagen content (picrosirius), collagen gene expression (Col1α1), 
hydroxyproline content, and markers for the presence of tissues macrophages that are 
supposed to be involved in fibrotic processes. The amount of detected MRI signal was of the 
same order of magnitude as the volume of lung injury in C57BL/6 mice (compare Figures 18B 
and 19A), and induced a tolerable initial body weight loss of less than 20%. In other words, in 
order to obtain a similar response in male BALB/c mice as that obtained in male C57BL/6 mice, 
the total bleomycin dose had to be increased by a factor of 10. This is consistent with previous 
results obtained using repeated IN administrations of bleomycin, showing that the responses 
induced by the same total dose of the antibiotic were approximately 10 times weaker in male 
BALB/c compared to male C57BL/6 mice [70]. Additionally to dose adaptation, it was tested in 
BALB/c mice whether the number of bleomycin administrations could be reduced from six to 
three. A threefold dose of 1.0 mg/kg bleomycin did not induce an adequate response as 
indicated by several readouts (Figure 19). A threefold dose of 2.0 mg/kg bleomycin (identical 
total dose as the preferred 6 x 1.0 mg/kg) was tested but excluded since the higher single dose 
evoked breathing interruptions. Therefore, a lower number of bleomycin administrations 
decreased the amount of induced lung fibrosis and is thus not recommended. 
In addition to dose reduction, changing from IN administration to OA of bleomycin evoked 
another improvement of the lung fibrosis model. There was a clear change apparent regarding 
localization of fibrotic lesions. Picrosirius staining (Figures 16C and 20C) showed a 
homogenous distribution of fibrotic lesions after OA in comparison to IN administration of 
bleomycin (Figure 16B). These different localizations of induced fibrosis can be explained by 
NIRF images of OA or IN administered Cy5.5 (Figure 17). Whereas 60 minutes after OA of Cy5.5 
the fluorescence signal could be detected all over the lung lobes (Figure 17B), the IN 
administered dye was localized in the trachea and the upper part of lung (Figure 17A). 
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Assuming that bleomycin is distributed in a comparable manner, this would explain why after 
IN administration of bleomycin the fibrotic lesions were primarily found around the main 
airways whereas the OA of bleomycin also induced fibrosis in the periphery of the lung. To 
have fibrotic areas in the lung periphery might be an important characteristic of a lung fibrosis 
model since this means a better comparability to the human disease where the deposition of 
collagen occurs with a peripheral distribution [100]. 
A similar distribution of fibrotic lesions could be found in rat lungs after OA of bleomycin. Since 
OA is not a commonly used method for lung instillation in rats, the feasibility was first tested 
in a small number of animals. The method was found to be easy, fast to apply and effective, 
since the amount of bleomycin that induced fibrosis was comparable to the amount in IT-
treated rats [27]. Thus, OA in rats should be taken into account when a less invasive alternative 
to IT administration is needed, for instance for multiple dosing. 
The UTE acquisition sequence for in vivo imaging has been optimized here for increased 
throughput in view of pharmacological applications. Compared to earlier work [70,72], the 
acquisition time of MR images of mice lungs could be considerably reduced by the use of the 
UTE sequence with short echo time. Although the method provides only a global view of the 
injury induced by bleomycin, the strong correlation (R=0.90, p<0.00001) between the signals 
quantified by MRI and the amount of collagen detected histologically (picrosirius staining) 
indicates that MRI reflected the development of fibrosis in the model. Moreover, although 
less strong, there was also a significant correlation between the MRI signals and the 
hydroxyproline content (R=0.48, p=0.005) as well as the expression of genes that are 
suggested to be involved in fibrotic processes. The expression of Col1a1, the gene that is 
encoding for the major component of type 1 collagen, but also the macrophage-specific 
expression of MMP12 and F4/80 [92-96] were highly correlated (p < 0.001) with the MRI 
signals.  
In summary, repeated OA administration of bleomycin led to sustained fibrosis in mice, with 
an acceptable initial weight loss of less than 15%. The method was easy to perform, fast and 
effective, as the total dose of bleomycin could be reduced compared to IN dosing. Moreover, 
a more homogeneous distribution of fibrotic lesions has been obtained than when using IN 
dosing. In rats, the OA route could be taken into consideration for repeated dosing. 
42 
 
 
4.2) MRI-detected, bleomycin-induced lung injuries in mice and rats: What is 
causing the observed changes in MRI signal? 
Introduction 
Pulmonary fibrosis is a lethal disease and characterized by the infiltration of inflammatory cells 
and remodeling of ECM including deposition of collagen [22-27]. For in vivo studies on 
pulmonary fibrosis, bleomycin (BLM), an antibiotic used for cancer treatment, is often 
administered to induce pulmonary fibrosis in small rodents [33-36]. It has been shown before 
that BLM-induced injuries can be quantified by MRI. The main limitation of the technique is 
its non-specific nature: although a good correlation to histologically determined collagen has 
been demonstrated [27,70], the exact nature of the MRI signals remains elusive as they can 
hardly be distinguished from inflammatory responses. It is unlikely that collagen itself is the 
main source of the MRI signals during fibrotic processes because of the lack of free protons. 
Most probably, as during inflammation, free water might induce these MRI signals.  
Proteoglycans as hyaluronic acid (HA) are, due their negative charge, able to attract water and 
are an important part of ECM. Since HA has been shown to be co-localized with collagen [101], 
to induce collagen production after subcutaneous administration [102,103], and was 
detectable (after subcutaneous administration) by MRI due to local increase of T2 [104], the 
possible role of HA on MRI signals in fibrotic lungs of mice has been investigated in this study.  
Therefore, hyaluronidase (HYAL), an enzyme degrading HA in humans and in small rodents, 
was administered via OA to BLM-treated mice and rats, with the aim to modulate the MRI 
signals induced by BLM. 
Material and Methods 
Ethics Statement 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(license number BS-1989). 
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Animals 
Seven- to 9-week-old C57BL/6 male mice (n=30) or SD rats (n=12) (Elevage Janvier, Saint 
Berthevin, France) were used throughout the study. Animals were kept at an ambient 
temperature of 22 ± 2°C under a 12 h normal phase light-dark cycle and fed NAFAG® pellets 
(Nahr- und Futtermittel AG, Gossau, Switzerland). Drinking water and food were freely 
available. 
Oropharyngeal aspiration of BLM or saline in mice 
Animals were lightly anesthetized with 2% isoflurane delivered in a box and BLM 
hydrochloride (0.1 mg/kg) in 40 µl of saline (0.9%) or vehicle (40 µl of saline (0.9%)) was 
administered via OA using a micropipette. OA was performed as described by de Vooght et al. 
[68]. Mice were fixed on a surgery board, the tongue was pulled out with a forceps, and the 
liquid was placed onto the distal part of the oropharynx while the nose was gently closed. As 
for the intra-nasal administration protocol, the procedure was performed six times 
consecutively, once daily. 
Oropharyngeal aspiration of BLM in rats 
Animals were lightly anesthetized with 3.5% isoflurane delivered in a box and BLM 
hydrochloride, 2 mg/kg in 100 µl of saline (0.9%) was administered via OA with a micropipette 
using a similar procedure as described above for mice.  
Administration of hyaluronidase and budesonide. 
16-160 U HYAL (from bovine testes, Sigma Aldrich, St. Louis, MO) dissolved in phosphate 
buffered saline (PBS, Life Technologies, Carlsbad, CA) and 1-3 mg/kg budesonide (BUD) (Sigma 
Aldrich, St. Louis, MO) solved in 2% dimethyl sulfoxide (DMSO) were administered via OA while 
the animals were lightly anesthetized with isoflurane delivered in a box (same procedures 
described for OA delivery of BLM). 
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Magnetic resonance imaging (MRI)  
During MRI signal acquisitions, animals were placed in supine position in a cradle made of 
Plexiglas. Body temperature was kept at 37±1°C using warm air or a heating pad. Following a 
short period of introduction in a box, anesthesia was maintained with 1.5% isoflurane for mice 
and 2% for rats in a mixture of O2/N2O (1:2), administered via a nose cone. All measurements 
were performed on spontaneously breathing animals; neither cardiac nor respiratory 
triggering was applied. As demonstrated earlier [70,72], averaging over several respiratory 
cycles suppressed artifacts caused by movements of the chest and the heart without the 
necessity of triggering the data acquisition. Measurements were carried out with a Biospec 
47/40 spectrometer (Bruker Medical Systems, Ettlingen, Germany) operating at 4.7 T and 
equipped with an actively shielded gradient system capable of generating a gradient of 200 
mT/m. The operational software of the scanner was Paravision (Bruker).  
An UTE sequence [73-75] with the following parameters was applied for the detection of BLM-
induced lung injury in mice: TR 20.0 ms, TE 601 µs, 604 projections, 2 averages, band width 
200 kHz, flip angle of the excitation pulse 25°, matrix size 192x192, slice thickness 1.4 mm and 
FOV 3.0 x 3.0 cm2. The total acquisition time was of 4.0 min for 10 consecutive axial slices 
covering the entire lung. A birdcage resonator of 32 mm diameter was used for excitation and 
detection. For rats an UTE sequence with the following parameters was used: TR 15 ms, TE 
801 µs, 604 projections, 2 averages, band width 200 kHz, flip angle of the excitation pulse 25°, 
matrix size 192x192, slice thickness 1.5 mm and FOV 6.0 x 6.0 cm2. The total acquisition time 
was of 7.25 min for 24 consecutive transverse slices covering the entire lung. A birdcage 
resonator of 70 mm diameter was used for excitation and detection. 
MR image analysis 
At a given time point, the area of BLM-induced lesions was quantified on each image from the 
dataset covering the whole lung, using a semi-automatic segmentation procedure 
implemented in the IDL (Interactive Data Language Research Systems, Boulder, Colorado, 
USA) environment on a Linux system. Images were first low-pass-filtered with a Gaussian 
profile filter and then transformed into a set of four grey level classes using adaptive Lloyd-
Max histogram quantitation. The highest class in the transformed images was extracted 
interactively by a region grower, whose border was drawn manually on each slice to control 
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the growing and limit it to areas within the lung (Figure 12). For each image, the area thus 
segmented by region growing corresponded to high intensity signals in the lung. The total 
volume of high intensity signals was then calculated by adding the areas obtained for each 
image from the dataset, and multiplying the summed value by the slice thickness. 
Segmentation parameters were the same for all analyzed images.  
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Animals were sacrificed with an overdose of thiopental (Pentothal®, Abbott; 250 mg/kg i.p., 
0.2 ml) immediately after an MRI acquisition. The trachea was immediately ligated to avoid 
collapse of the lung. Removed lung tissue was stabilized in RNA later (Ambion, Zug, 
Switzerland; #AM7021,) and stored at -80°C until use. For RNA purification, samples were 
transferred to a 2 ml Eppendorf tube with 1000 µl of RLT buffer (Qiagen, Hombrechtikon, 
Switzerland; #79216) and β-mercaptoethanol (Sigma-Aldrich, Buchs, Switzerland; #M3148 ) 
and one stainless bead (Qiagen, #69989). Samples were homogenized (Qiagen Tissue Lyser, 
#85300) in two to three 1-min runs at 30 rotations/s each, with 1 min on ice between the runs. 
After centrifugation for 3 min at 13 000 rpm, 4°C, 300 µl of the resulting supernatant were 
processed on the Rneasy Mini Kit (Qiagen, #74106 ) with a DNAse digestion step (Qiagen, 
#79254), accordingly to the manufacturer’s protocol. 
Resulting total RNAs were quantified on a NanodropTM system (Wilmington, DE, USA) and 1 
µg was reverse-transcribed using the high capacity cDNA RT kit (Applied Biosystems, Zug, 
Switzerland; #4368813). 
Expression of the different genes of interest was evaluated by real time PCR using the ABI 
Prism 7900HT system. Briefly, 10 ng/µl equivalent RNA per well was distributed in a 384 well 
plates (Applied Biosystems, #4326270), with 5 µl of the Taqman Universal Mastermix 2X kit 
(Applied Biosystems, #4324020) and 0.5 µl of 20X Assay-on-demand mix  Taqman probe 
(Applied Biosystem, #4331182). The different probes used and respective genes were: 
Mm00476206_m1 (HYAL1), Mm01230689_g1 (HYAL2), and Mm00662097_m1 (HYAL3). 
Expression for each sample was normalized to HPRT (Mm03024075 m1) and compared to the 
vehicle-treated group, using the 2-∆CT formula. The expression of HPRT was the same in both 
analyzed groups. 
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Results 
HYAL induced changes in BLM-induced MRI signals in mice 
In a proof-of-concept study, eight male C57BL/6 mice have been treated with 0.1 mg/kg BLM 
on six consecutive days. Twelve days after the last administration, half of the animals were 
treated with 16 U of HYAL while the other four animals received PBS as negative control. 
Additionally, 16 U of HYAL were administered to two saline-treated animals. Within 24 h the 
evaluated MRI signal volume tended to increase in HYAL-treated animals, while the average 
signal volume in both control groups did not change (Figure 21A). The signal increase in the 
BLM group relative to baseline was about 90 µL at that time point. At 40 days after last BLM 
administration, a time point at which the MRI signal was still 50 µL above baseline, another 
dose of HYAL (16 U) induced a slight increase in MRI signal volume in the BLM group overnight 
but no changes in the control group (Figure 21B).  
 
It has been suggested that parts of the ECM and therewith small fragments of hyaluronic acid, 
which is a degradation product produced by HYAL, are involved in inflammatory processes 
[105-108]. To investigate whether the observed signal increase could have been caused by 
inflammation, the same mice were again treated with HYAL/PBS on day 51 after BLM and 
received3 mg/kg BUD after MRI measurements on day 52. The increased MRI signal in BLM- 
and HYAL-treated animals was reduced by BUD and reached initial level within 24 h (Figure 
Figure 21: Differential MRI signal volume 24h after HYAL/PBS treatment at A) day 12 and B) day 40 after last BLM 
administration. For statistical analysis one-way ANOVA with Fisher-Test was applied. 
 
47 
 
  
22). The combination of BUD and HYAL was then tested in another cohort of n=10 BLM 
challenged C57BL/6 mice. At day 14 after last BLM challenge (6x0.1mg/kg), treatment started 
with 1 mg/kg BUD. On the following three days 16 U of HYAL were administered once daily. 
Mice in the control group (n=8) received vehicle once daily. After two weeks of treatment the 
relative MRI signal volume was decreased in both groups, but the relative MRI signal volume 
was slightly lower in the HYAL- and BUD-treated animals (Figure 23). 
HYAL induced changes in BLM-induced MRI 
signal in rats  
A combined treatment of BUD (1mg/kg) 
and HYAL (160 U) was administered to 
BLM-challenged SD rats. Twelve days after 
induction of PF by administration of 2 
mg/kg BLM via OA, 1 mg/kg BUD was 
administered via OA directly after MRI 
measurements. On day 13 another 
imaging session was performed and the 
animals were then treated with either 
HYAL (160 U) or vehicle.  No significant 
change in MRI signal volume occurred 24 
h after BUD administration, while the 
signal volume  decreased 24 h after 160 
U of HYAL (Figure 24). The difference in 
MRI signal between the two groups 
stayed until day 20 after BLM challenge. 
Gene expresseion of HYAL increased in the 
mice BLM model 
Gene expression of three types of HYAL 
(1-3) was determined in lung tissue taken 
from saline- (n=8) and BLM-treated 
(6x0.5mg/kg i.n.; n=7) C57BL/6 mice at 
day 14 after last challenge. Figure 25 
Figure 23: Combination treatment of HYAL and BUD on PF in 
mice. A Dose of 1mg/kg BUD was followed by three times 16U 
HYAL per mouse on three following days. Eighteen animals were 
used for the study; n=10 for Bleo/HYal group and n=8 for the 
Bleo/Veh group t(wo animals  had to be sacrificed because of 
high body weight loss. For Statistical analysis Two-Way repeated 
measures ANOVA with Tukey-Test was applied. 
 
Figure 22: Influence of HYAL and BUD on MRI signal volume 
at day 51 after last BLM administration in mice. HYAL 
induced a slight increase in BLM-treated mice. For Statistical 
analysis Two-Way repeated measures ANOVA with Tukey-
Test was applied. 
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shows a reduced expression of the three types of HYAL in BLM- compared to saline-treated 
mice. 
Discussion 
In this small pilot-study, the hypothesis was 
investigated whether HA, a part of ECM, co-
localized with collagen [101] and able to 
attract water, could be contributing to the 
MRI signals detected after BLM 
administration. HA plays a role in PF and its 
production was shown to be increased in 
humans [109] and rats [110]. A further 
indication that HA is involved in fibrotic 
processes is given in this study by the gene 
expression of HYAL1-3. Cheng et al. have 
already shown that the expression of HYAL 1 & 2 was decreased in a murine model of asthma, 
while the expression of hyaluronan synthase 1 & 2, the enzyme responsible for HA production, 
was increased [101]. In the murine BLM model for PF, the relative gene expression of HYAL1 
was reduced and HYAL2-3 showed a tendency to a reduced expression.  
After administration of HYAL, the enzyme which is degrading HA, the MRI signal showed a 
tendency to increase in mice at an early time point after BLM administration (day 12) and a 
significant increase at late time points (days 40 and 51; Figure 21 and 22). The observed signal 
increase was consistent with  published data suggesting that small fragments of HA, resulting 
Figure 24: Combined treatment of HYAL and BUD on PF in BLM-
treated rats (n=6+6). A dose of 1mg/kg BUD on day 12was followed 
by OA of 160U HYAL per rat. For Statistical analysis Two-Way 
repeated measures ANOVA with Tukey-Test was applied. 
 
Figure 25: Relative gene expression of HYAL1-3 in lung tissue of saline- and BLM-treated mice (n=8 and n=7, respectively), 
14 days after last challenge. HPRT was used as housekeeping gen. For Statistical analysis One-Way ANOVA with Tukey-
Test was applied. 
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from HA degradation, are involved in inflammatory processes [105-108]. Administration of an 
anti-inflammatory drug (budesonide) led to a reduction of the MRI signal, which supports the 
hypothesis that the observed signal increase in HYAL-treated mice was due to inflammatory 
processes (Figure 22). After a combined treatment with HYAL and budesonide the MRI signal 
could be reduced in BLM-challenged mice and rats (Figures 23 and 24). The observed changes 
in MRI signal might not have represented a therapeutic effect, since no effect of HYAL and 
budesonide could be observed histologically or by hydroxyproline determination (data not 
shown), but it indicates that the MRI signal can be modulated by HYAL, even though the 
changes are small.  
Overall the data of this pilot study support the hypothesis that HA plays a role in the 
appearance of BLM-induced changes in MRI signal. Since HA has been shown to be involved 
in fibrotic processes [109,110] and co-localized with collagen [101], the data strengthen the 
detection of BLM-induced injuries by MRI as a noninvasive in vivo readout for PF. 
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Introduction 
Pulmonary fibrosis, a progressive and lethal disease that is characterized by proliferation of 
fibroblasts and declined lung function, leads to lung damage including accumulation of 
connective tissue, interstitial pneumonia, and respiratory bronchiolitis [1-3].  A patchy alveolar 
wall fibrosis develops in patients with chronic obstructive pulmonary disease (COPD) whereas 
in chronic asthmatics, a fibrotic response occurs predominantly in the lamina reticularis, 
leading to thickening of the basement membrane [17,18]. In both cases the ongoing 
inflammation-repair cycle leads to permanent structural changes in the airway wall 
(remodeling) of which fibrosis is a major constituent [19,20].  
Although the pathway of remodeling during the fibrotic processes is still not completely 
understood, it is so far known that the lung structure is altered by the infiltration of 
inflammatory cells, thickening of the alveolar walls and deposition of collagen, elastin, and 
proteoglycans [22-27,111,112]. These changes in lung structure lead to an impairment of lung 
function. Increased lung tissue resistance and elastance, as well as decreased compliance have 
been shown in humans [2,15] and in small rodent pulmonary fibrosis models [23-25,28-31].  
Moreover, changes in tidal volume and breathing cycle times have been shown in a mouse 
fibrosis model [113].   
Treatment with bleomycin, an antibiotic with activity against gram-negative bacteria [32] and 
chemotherapeutic properties [114,115], leads to pulmonary fibrosis in about 18% of patients 
[116,117]. Therefore, bleomycin has become the mainly used substance to model pulmonary 
fibrosis in small rodents [39,118,119]. Several studies have shown that bleomycin instilled 
directly into the lung of small rodents elicits an early inflammatory and a late fibrotic response 
[33-36]. Application of bleomycin causes an acute inflammatory reaction and fibrotic changes 
that resemble human fibrotic lung disease both histologically and physiologically [22,39].  
The availability of the bleomycin model of pulmonary fibrosis provides the opportunity to 
investigate in vivo novel pharmacological approaches aiming to treat this crippling disease 
[118]. Non-invasive readouts are of importance in the frame of pharmaceutical research, since 
the ongoing mechanisms during the development of pulmonary fibrosis are still not 
completely known and target identification and development of therapeutics against PF are 
challenging. We reported the use of MRI to non-invasively follow the course of lung injury 
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induced by bleomycin administration to mice [70,120] and  rats [27,120,121].  The ability of 
MRI to non-invasively quantify lung injury in bleomycin-treated animals facilitates in vivo 
pharmacological studies in the model. Repetitive measurements open new avenues in testing 
compounds as the responses at several time points during the course of treatment can be 
easily compared. Specifically, studies at the chronic phase, when fibrosis is already 
established, become amenable. 
The present work shows that remodeling of lung tissue, which is induced by OA of bleomycin 
in rats, leads to an increase of lung tissue weight and lung volume, which can be non-invasively 
quantified by MRI. The characterization of lung volume changes in the bleomycin model was 
motivated by the fact that they impact lung function. 
Material and Methods 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(licenses BS-1989 and BS-2565). 
Animals 
Seven- to nine-week-old SD rats (n=44, age at the beginning of the study) from Elevage Janvier, 
Saint Berthevin, France, were used throughout the study. Animals were kept at an ambient 
temperature of 22 ± 2°C under a 12 h normal phase light-dark cycle and fed NAFAG® pellets 
(Nahr- und Futtermittel AG, Gossau, Switzerland). Drinking water and food were freely 
available. 
Oropharyngeal aspiration of bleomycin or saline in rats 
Animals were lightly anesthetized with 2.5% isoflurane (Abbott, Cham, Switzerland) delivered 
in a box and bleomycin hydrochloride (2-3 mg/kg; Teva, Basel, Switzerland) in 100 µl of saline 
(0.9%) or vehicle (100 µl of saline (0.9%)) was administered via OA using a micropipette. OA 
was performed as described earlier [120]. Rats were fixed on a surgery board, the tongue was 
pulled out with a forceps, and the liquid was placed onto the distal part of the oropharynx 
while the nose was gently closed.  
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Magnetic resonance imaging (MRI)  
During MRI signal acquisitions, animals were anaesthetized and placed in prone position in a 
cradle made of Plexiglas. Body temperature was kept at 37±1°C using a heating pad. Following 
a short period of introduction in a box, anesthesia was maintained with 2.0% isoflurane in a 
mixture of O2/N2O (1:2), administered via a nose cone. Measurements were performed on 
spontaneously breathing animals. Measurements were carried out with either a Biospec 
47/40 or a 70/30 spectrometer (Bruker Medical Systems, Ettlingen, Germany) operating at 4.7 
or 7.0 T, respectively. The operational software of the scanners was Paravision (Bruker).  
An UTE sequence [73-75] with the following parameters was used for non-gated applications: 
RT 15.0 ms, TE 801 µs, 604 projections, 2 averages, band width 200 kHz, flip angle of the 
excitation pulse 25°, FOV 6.0 x 6.0 cm2, matrix size 192x192, and slice thickness 1.5 mm. The 
total acquisition time was of 7.25 min for 24 consecutive transverse slices covering the entire 
lung. In order to have faster acquisitions, a gradient-echo sequence with the following 
parameters was used for respiratory-gated acquisitions:  TR 15.0 ms, TE 2.520 ms, 8 averages 
(4 averages for gated acquisitions), flip angle of the excitation pulse 10°, FOV 5.0 x 5.0 cm2, 
matrix size 256x128, and slice thickness 2.0 mm.  Eighteen to twenty-four consecutive 
transverse slices covered the entire lung. A birdcage resonator of 72 mm diameter was used 
for excitation and detection. 
Respiratory-gated acquisitions 
Most acquisitions were performed in spontaneously breathing rats, without gating. For 
selected experiments, however, it was of importance to acquire images in different 
respiratory phases of the animal. Therefore, acquisition has been triggered using a small 
animal monitoring and gating system (model 103—IBP-50, SA Instruments, Inc., Stony Brook, 
NY, USA). The breathing rate was monitored and kept between 50 and 60 strokes per minute 
(regulation via anesthesia level). For obtaining images of the lung at the inflated state, data 
acquisition was performed for a duration of approximately 200 ms with respect to the 
inspiration peak of the respiratory cycle. The inverted trigger-signal of the breathing cycle was 
used to acquire data in order to reconstruct images reflecting the lung in the deflated state.  
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Evaluation of Lung Volume 
To evaluate lung volumes (which is defined for this work as total volume of the lung, including 
tissue, air, and airways), regions of interest (ROI) have been manually drawn around the lung 
on each acquired slice using the software Paravision. The calculated areas of all ROIs for one 
animal have been added and multiplied by the slice thickness, resulting in the total lung 
volume.  
Post-mortem analyses 
Animals were sacrificed with an overdose of thiopental (Pentothal®, Abbott; 250 mg/kg i.p., 
0.2 ml) immediately after an MRI acquisition. The trachea was ligated to avoid total collapse 
of the lung for histological analysis. For determination of wet weight, dry weight, and 
hydroxyproline content, all lung lobes were removed without trachea and bronchi.  
Histology 
Histological analysis was performed as described in more detail earlier [27,120].  Lung lobes 
were immersed in 10% neutral buffered formalin for 24 h. Following fixation, lungs were 
trimmed, and three transverse slices were cut through the left lung (superior, median, and 
caudal parts) to include the main bronchi as well as the pulmonary alveoli. Sections were then 
dehydrated through increasing graded series of ethylic alcohol and embedded in one block of 
paraffin wax. Serial sections (3 µm) were stained with picrosirius red for the identification of 
collagen fibers and newly synthesized collagen. 
Determination of hydroxyproline in lung tissue samples 
Lung tissue samples were weighed, dried in an oven at 90°C overnight, and the weight was 
recorded again. Dry tissues were then boiled in 0.5 mL of 6 M HCl at 120°C overnight (8-16 
hours) in Pyrex tubes with heat- and acid-resistant screw-on caps (article TES-830-70G; Fisher 
Scientific, Wohlen, Switzerland). After cooling down and adding 5 µL of phenolphthalein (1%), 
the samples were neutralized with NaOH 10 M (Sigma N°S-5881) and 6 M HCl. Black 
precipitate and brown color was removed by adding 100 µL of carbon suspension [10 mg/mL 
activated charcoal (article C4386; Sigma-Aldrich, Buchs, Switzerland) in water], centrifugation, 
and filtration. Five microliters of standard or hydrolyzed sample were pipetted in triplicates 
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onto a 96 well plate, and 5 µL citrate acetate buffer (5% citric acid, 7.2% sodium acetate, 3.4% 
sodium hydroxide, 1.2% glacial acetic acid, distilled water) was added to each well, as well as 
100 µL of freshly prepared chloramine-T solution (14.1mg chloramine-T, 0.1mL n-propanol, 
0.1mL distilled water, 0.8mL citrate acetate buffer). The samples were then incubated at room 
temperature for 20 minutes. After adding 100 µL of Ehrlich’s reagent (2.5 g of 4-
(dimethylamino)benzaldehyde, 9.3 mL of n-propanol, and 3.9 mL of 70% perchloric acid), the 
wells were incubated for 20 minutes at 65°C. After cooling down, the samples were measured 
at 550 nm on a spectrophotometer (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, 
USA); a standard curve from 5 to 100 mg hydroxyproline in water was created. Data were 
expressed as µg/right lung lobe. 
Statistics 
For statistical analysis the software SigmaPlot™ (Systat Software Inc., San Jose, CA, USA) has 
been used. One-way ANOVA and t-tests have been performed for endpoint readouts while 
Two-way repeated measures ANOVA with Tukey tests have been used for readouts with 
multiple measurements. The following abbreviations were used for the indication of 
significance: */#: 0.01<p<0.05; **/##: 0.001≤ p ≤ 0.01 ***/ ###: p< 0.001. 
Results 
Bleomycin induces an increase in MRI detected lung volume in rats 
SD rats that have been treated with a single dose of bleomycin (2mg/kg OA) showed enlarged 
lung areas on non-gated UTE-MR images (Figure 26A). Therefore, lung volume of bleomycin 
challenged rats have been determined, by defining the lung area on each image and 
calculating the lung volume as described in the method section, and compared to the lung 
volume of healthy animals. Within seven days bleomycin-treated rats showed a significant 
increase in MRI-detected lung volume (Figure 26B) that persisted until the end of the 
experiment (21 days after challenge). The determined lung volume of bleomycin treated rats 
was significantly higher compared to vehicle group, even though the lung volume of healthy 
animals increased slightly with age. 
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Influence of breathing rate and physiological growth on lung volume detected by non-
triggered UTE-MRI 
Non-triggered MRI acquisitions of the lung result in an averaged image over all respiratory 
phases [122]. Factors as for instance bodyweight and therewith growth of lung or breathing 
rate of the animal might have an influence on the evaluated lung volume. In a first study we 
investigated the influence of breathing rate, length of narcosis and body weight on detected 
lung volume. Six healthy SD rats have been imaged by UTE-MRI during four weeks. During all 
imaging sessions the breathing rate has been monitored. No correlation has been found 
between the lung volume assessed by MRI and the breathing rate (Figure 27A). In order to 
investigate the possible influence of time in anesthesia on the detected lung volume, a second 
image has been acquired approximately 15 minutes after the first acquisition (resulting in a 
total anesthesia time of about 35 minutes, including induction time).  When the animals were 
kept for a longer time in anesthesia, the detected lung volume decreased (Figure 27B).  
Therefore, in routine applications and non-gated acquisitions, care was taken to maintain the 
total anesthesia time approximately the same and under 15 minutes per session.  
Saline-treated animals showed a slight increase in lung volume over 21 days (Figure 26B). This 
effect may be rather explained by physiological lung growth than by effects of saline 
Figure 26: Bleomycin-treated rats showed increased total lung volumes as compared to control, saline-challenged animals. 
A) Images acquired at 7 T of saline- (left) and bleomycin-treated rats (right), 14 days after challenge; arrows point to enlarged 
lung areas. B) Quantified increase of MRI-detected lung volume in bleomycin treated rats (n=5) compared to saline treated 
animals (n=5). Data are shown as mean ± STDEV; significance level above bars mean significance to baseline; Two-way 
repeated measures ANOVA was applied. 
 
57 
 
  
instillation. Formulas that were published by Mirfazaelian et al. [123] for calculating the 
weight of certain rat organs led suggest that the rat lung can grow until the age of 
approximately 14 weeks (Figure 27C). For predicting the physiological increase in lung volume, 
the ratios between the lung wet weights and the corresponding MRI-detected lung volumes 
have been assessed from several studies, resulting in an averaged lung density of 0.21±0.019 
mg/mL (±STDEV). Introducing the averaged lung density into the formula of Mirfazaelian et al. 
[123], the increase of lung volume due to growth has been predicted
  
Figure 27: A) Correlation between breathing rate (breaths per minute) and MRI-detected lung volume. Lung volume of 
2x6 naïve or saline-treated rats at seven different time points within 3 weeks have been evaluated. One symbol 
represents one group of six rats at one time point; Linear Fit showed no significant p-value B) Influence of narcosis on 
MRI-detected lung volume in n=6 animals at two different time points. The time between the first and the second 
acquisition was about 15 minutes; Lines are linking results of the same animal. C) Prediction for lung wet weight 
development in SD rats using the formula of Mirfazaelian et al. [123]. D) Prediction for lung volume of naïve SD rats (grey 
curve) using the formula of Mirfazaelian et al. [123] and averaged lung density of collected data from several studies. MRI-
detected lung volumes for naive animals and bleomycin treated rats are shown as mean ± STDEV; arrows point to 
treatment start. 
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(Figure 27D). The lung volumes of naive SD rats (n=6) assessed by UTE-MRI were comparable 
to the predicted lung volumes (Figure 27D). The administration of different doses of bleomycin 
in rats of different age let in all cases to an increase in MRI-detected lung volume, that clearly 
differed from the physiological growth of lung volume in naive rats (Figure 27D). 
Characterization of lung volume detected by MRI 
Twelve male SD rats have been examined during three weeks by MRI. After baseline 
measurements all animals have been treated with either 100 µL of saline (0.9%) or bleomycin 
(2mg/kg) via OA. At each time point, a non-triggered acquisition was followed by two gated 
acquisitions to reflect inflated and deflated state, as described in the methods section.  
 
 
Figure 29: Post-mortem analysis A) Terminal lung wet weight, two weeks after challenge; data are shown as mean ± STDEV; 
One-way ANOVA was performed. B) Terminal lung dry weight, two weeks after challenge; data are shown as mean ± STDEV; 
One-way ANOVA was performed. C) Hydroxyproline content in all five lung lobes, two weeks after challenge; data are shown 
as mean ± STDEV; One-way ANOVA was performed. 
 
 
 
Figure 28: MRI-detected lung volume of saline (n=6) and bleomycin (2mg/kg) treated rats (n=6) in different phases of 
breathing cycle. A) Non-triggered MRI. B) Vins, Lung Volume in the inflated state. C) Vexp, Lung volume in the deflated state. 
Data are shown as mean ± STDEV;  Significance level result from comparison to saline group at the same time point. Two-
way repeated measures ANOVA was applied.  
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Bleomycin-treated animals showed, compared to the vehicle group, a significant increase in 
non-triggered-MRI detected lung volumes (Vntri); similarly, the volumes of inflated (Vins) and 
deflated lungs (Vexp) were also increased (Figure 28A-C). Animals of the control group showed 
a slight increase in lung volumes that was comparable to the increase in lung volume of naive 
animals (Figure 28A-C, see also Figure 27D). The wet and dry weight of all five lung lobes have 
been determined post-mortem and were significantly higher in the bleomycin group (Figure 
29A-B). The hydroxyproline content, determined in all five lung lobes, was significantly 
increased after bleomycin administration (Figure 29C). The relative water content was the 
same in both groups (79.3 % for saline, 79.2% for bleomycin group). Correlations between the 
lung volumes derived by MRI (non-triggered and triggered acquisitions), dry and wet lung 
weights, as well as hydroxyproline content are presented in Figure 30A-D.  
Figure 30: A) Correlation between lung wet weight and MRI-detected lung volume in expiration phase (Vexp) of saline and 
bleomycin treated SD rats (n=6+6) two weeks after challenge. B) Correlation between lung dry weight and MRI-detected 
lung volume in expiration phase (Vexp) of saline and bleomycin treated SD rats two weeks after challenge. C) Correlation 
between hydroxyproline content of all five lung lobes and MRI-detected lung volume in expiration phase (Vexp) of saline 
and bleomycin treated SD rats. D) Correlation between MRI-detected lung volume in expiration phase and without 
triggering. 
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Figure 31 summarizes 
histological evidence of 
collagen deposition in the 
lungs of rats treated with 
bleomycin (2 mg/kg, OA 
route). Histology also 
revealed perivascular, 
peribronchial and 
parenchymal infiltration of 
inflammatory cells. 
However, no edema has 
been detected. Also, no 
emphysema was present in 
the lung sections. 
Discussion 
Despite substantial research during the last years, currently no efficacious therapy and only 
few non-invasive in vivo diagnostic tools for lung fibrosis exist.  The availability of such 
methods and a representative animal model would be of great importance for the 
development of therapeutics against lung fibrosis. It has been shown in former studies that 
fibrosis can be modeled by the instillation of bleomycin into the lung [39,97]. Induction of lung 
fibrosis by instillation of bleomycin has often been used to investigate the effect of potential 
therapeutics or the influence of genes on the development of lung fibrosis for target finding 
[33,98,99].  
It has been shown earlier that proton MRI techniques are able to non-invasively follow the 
progression of bleomycin-induced lung injury in rats [27,120,121,124] and mice [33,120].  The 
signals quantified by MRI in the lung showed high correlation to histological analysis of 
collagen and to hydroxyproline content.  In the present work we aimed at validating lung 
volume as an alternative readout that might reflect changes in lung function in the model, 
since the improvement of lung function is a main aim for therapeutics against several lung 
diseases. 
Figure 31: Histological analysis of bleomycin treated (2mg/kg, OA) left rat lung 
lobes, at day 21 after administration of the antibiotics. A) Picrosirius staining; 
yellow areas represent picrosirius stained collagen ; View under bright field light (B)  
and polarized light (C); D) 20x magnified view under brightfield light ; neither 
emphysema nor edema could be observed. 
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The lung volume detected by non-triggered MRI increased after instillation of bleomycin 
(Figures 26 and 27D). An increase in lung volume has also been reported earlier for non-
triggered MRI acquisitions of spontaneously respiring rats following an intra-tracheal 
administration of elastase [125], due to emphysema induced by the enzyme. No emphysema 
could be observed in histological analysis of rat lungs after instillation of 2 mg/kg bleomycin 
(Figure 31). Also, the presence of edema was excluded by histology and by the fact that the 
relative water content of 79% did not change upon instillation of bleomycin (data not shown). 
Breathing rate or anesthesia showed no or only slight influence on MRI-detected lung volume 
and could not explain the observed increase after instillation of bleomycin (Figure 27A,B). 
Finally, the increase in lung volume after bleomycin administration was clearly more 
pronounced than that expected from the physiological growth-curve (Figure 27D). Therefore, 
the increase in lung volumes following bleomycin detected with non-gated MRI acquisitions 
had to be related to either anatomical or lung function changes, or by a combination of both.  
Similarly to non-gated images, respiratory-triggered acquisitions of bleomycin-challenged rats 
showed a significant increase in lung volume both in the inflated (Vins) and deflated (Vexp) 
state (Figure 28A-C). Therefore, the increase in lung volume on non-gated images of 
bleomycin-treated animals evolved from a significant increase of Vins but also Vexp. Since 
neither emphysema nor edema could be observed in this model, the increase in lung volume 
after expiration (Vexp) can only be explained by either air that remained in the lung as a 
consequence of a loss in lung function or by tissue remodeling due to the deposition of 
collagen, elastin, and proteoglycans [22-27]. The post-mortem assessed lung wet and dry 
weight, as well as hydroxyproline content (Figure 29A-C) and picrosirius staining (Figure 31) as 
markers for collagen deposition, were all increased in bleomycin-treated rats.  These 
observations indicate that the increase in MRI-assessed lung volumes in the bleomycin group 
(Figure 28A-C), particularly of Vexp was due to tissue deposition (remodeling) induced by the 
antibiotic. This suggestion is reinforced by the correlation of Vexp to lung wet weight (Figure 
30A), dry weight (Figure 30B) and hydroxyproline (Figure 30C): an examination of the linear 
fits reveal that an increase of Vexp from 8 to 10 mL  corresponded to a relative increase of the 
other readouts (Figure 30A-C)  by the same amount (around 25%) The strong correlation of 
Vexp to Vntri (Figure 30D) with a ratio of about 1.0 demonstrates that not only volume 
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assessments at the expiratory phase (Vexp) but also the less time-consuming non-gated 
assessments (Vntri) provide a readout for bleomycin-induced tissue deposition in rats.  
Tissue deposition in the lung, as for instance collagen, elastin, and proteoglycans, induced by 
bleomycin correlates to an increase in lung resistance [23,24,26,111,112] and therewith to a 
decrease in lung compliance. Therefore, MRI-detected alterations in lung volume, which in 
this work were shown to be related to increases of lung wet and dry weight as well as of 
collagen content, may also be considered as reflecting changes of lung function in the model. 
As measurements are performed in spontaneously breathing rats, it is recommended to keep 
the animals at approximately the same time in anesthesia (at maximum 20 minutes) in each 
imaging session, since prolonged anesthesia may lead to a reduction of the total lung volume. 
Moreover, the physiological growth of the lung needs to be taken into account by the 
incorporation of appropriate control groups or by correcting the assessed lung volumes using 
the formula of Mirfazaelian et al. [123]. As therapies aim primarily at improving the lung 
function, incorporation of this readout into pharmacological testing in the bleomycin model 
could be of interest. Further pharmacological validation and comparison to invasive functional 
tests is warranted in order to qualify this anatomical readout as noninvasive marker of 
changes in lung function in spontaneously breathing, bleomycin-challenged rats. 
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5) MRI-detected effects of two compounds on pulmonary fibrosis in 
the bleomycin model 
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Introduction 
Pulmonary fibrosis, characterized by fibroblast proliferation and ECM remodeling, is the end 
result of diverse types of severe lung damage that include usual interstitial pneumonia, 
desquamative interstitial-pneumonia, non-specific interstitial pneumonia, respiratory 
bronchiolitis interstitial lung disease, and acute interstitial pneumonia [1-3]. In patients with 
chronic obstructive pulmonary disease a patchy alveolar wall fibrosis develops whereas in 
chronic asthmatics, a fibrotic response occurs predominantly in the lamina reticularis, leading 
to a thickening of the basement membrane [17,18]. In both cases the ongoing inflammation-
repair cycle leads to permanent structural changes in the airway wall (remodeling) of which 
fibrosis is a major constituent [19,20]. However, up to 50% of the cases of pulmonary fibrosis 
are defined as IPF [21]. Current therapies for IPF are not particularly effective and involve 
treatment with corticosteroids and other immunosuppressive/cytotoxic agents such as 
prednisone and cyclophosphamide [126]. 
Bleomycin (BLM) is an antibiotic with activity against gram-negative bacteria [32] that also 
possesses chemotherapeutic properties and is highly efficient in some types of carcinomas. 
However, BLM produces a dose-dependent pulmonary fibrosis in most patients [21]. A single 
IT instillation of BLM is commonly used to induce experimental pulmonary fibrosis in rodents 
[33-35]. In this animal model, the single application of the antibiotic causes an acute 
inflammatory reaction and fibrotic changes that resemble human fibrotic lung disease both 
histologically and physiologically [22,39]. The availability of this animal model of pulmonary 
fibrosis provides the opportunity to investigate novel pharmacological approaches that can be 
used to treat and prevent this crippling disease. 
Talabostat mesilate (PT100) is an orally active, specific inhibitor of dipeptidyl peptidases, 
including tumor-associated fibroblast activation protein (FAP) [127]. By an independent 
mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to 
engender a tumor-specific host immune response, thus giving it a unique dual mechanism of 
action. In clinical trials, talabostat has demonstrated significant activity, including achieving 
complete responses in patients with non-small-cell lung cancer and malignant melanoma. In 
house, the compound has shown encouraging results in a mouse kidney fibrosis model. These 
data provide the rationale for testing the compound in a second fibrosis model. 
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In the present study proton MRI was applied to assess non-invasively and in spontaneously 
breathing mice the effects of PT100 on established fibrosis following repeated IN application 
of BLM [70]. Post-mortem histological and qRT-PCR analyses were performed on lung samples 
to validate the MRI readouts. 
Methods 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(license number 1989). 
Animals 
Seven- to 9-week-old C57BL/6 male mice (n=32, Charles River, L’Arbresle, France) were used 
throughout the study. Animals were kept at an ambient temperature of 22 ± 2°C under a 12 h 
normal phase light-dark cycle and fed NAFAG® pellets (Nahr- und Futtermittel AG, Gossau, 
Switzerland). Drinking water was freely available. 
Intra-nasal administration of bleomycin or saline 
Mice were lightly anesthetized with 1.5% isoflurane (Abbott, Cham, Switzerland) in a chamber 
and bleomycin hydrochloride (0.5 mg/kg; Euro Nippon Kayaku, Frankfurt am Main, Germany) 
in 25 µl of saline or vehicle (25 µl of saline) was administered IN via a micropipette (12.5 µl per 
nostril). This procedure was performed six times, on days -7, -6, -5, -2, -1, 0.  
Study groups 
PT100 (NVP-CGQ158-AA-3; 40 µg/mouse, dissolved in 0.9%NaCl) or vehicle was dosed per os 
(p.o.) by gavage twice daily (at approximately 8 am and 5 pm) from day 1 to day 14 after last 
BLM application. Animals were divided into the following groups: Saline-challenged mice (n=8) 
have been treated with PT100 vehicle (0.9%NaCl), BLM-challenged mice (n=12) with PT100 
vehicle, and BLM-challenged mice (n=12) with PT100. 
Mice were randomized into groups 2 or 3 according to the BLM-induced responses detected 
by MRI at day 0, in order to have the same mean lesion volumes in both treatment groups at 
the beginning of compound dosing. Animals displaying a weight loss of more than 20% were 
sacrificed before the end of the study. 
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Magnetic resonance imaging (MRI) 
During MRI signal acquisitions, mice were placed in supine position in a cradle made of 
Plexiglas. Body temperature was maintained at 37±1°C using warm air. Anesthesia was 
maintained with 1.3% isoflurane, in a mixture of O2/N2O (1:2), administered via a nose cone. 
All measurements were performed on spontaneously breathing animals; neither cardiac nor 
respiratory triggering was applied. As demonstrated earlier [72] averaging over several 
respiratory cycles suppressed artifacts caused by movements of the chest and the heart 
without the necessity of triggering the data acquisition. Measurements were carried out with 
a Biospec 47/40 spectrometer (Bruker Medical Systems, Ettlingen, Germany) operating at 4.7 
T and equipped with an actively shielded gradient system capable of generating a gradient of 
200 mT/m. The operational software of the scanner was Paravision (Bruker).  
An UTE sequence [73] with the following parameters was applied for the detection of BLM-
induced lung injury: TR 9.5 ms, TE 651 µs, 314 projections, 32 averages, band width 200 kHz, 
flip angle of the excitation pulse approximately 10°, matrix size 150x150, slice thickness 1.4 
mm and FOV 2.5x2.5 cm2. The total acquisition time was of 15.9 min for 10 consecutive 
transverse slices covering the entire lung. A birdcage resonator of 32 mm diameter was used 
for excitation and detection. 
MR image analysis 
At a given time point, the area of BLM-induced lesions was quantified on each of the 10 images 
covering the whole lung, using a semi-automatic segmentation procedure implemented in the 
IDL (Interactive Data Language Research Systems, Boulder, Colorado, USA) environment on a 
Linux system. Images were first low-pass-filtered with a Gaussian profile filter and then 
transformed into a set of four grey level classes using adaptive Lloyd-Max histogram 
quantitation. The highest class in the transformed images was extracted interactively by a 
region grower, whose border was drawn manually to control the growing (Figure 12). The total 
volume of high intensity signals was calculated by adding the areas obtained for each of the 
10 images, and multiplying the summed value by the slice thickness. Segmentation 
parameters were the same for all analyzed images, chosen to segment regions corresponding 
to high intensity signals. Because the lesion signals and those from vessels were of comparable 
intensities, the volume corresponding to the vessels was assessed on baseline images and 
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then subtracted from the volumes determined on post-treatment images. Differential signal 
volumes (parsed, baseline-subtracted data) reflecting the BLM effects are presented. Thus, for 
each mouse, the volume of high intensity signals present in baseline images was subtracted 
from the volumes evaluated at later time points. 
Post-mortem analyses 
Animals were sacrificed with an overdose of thiopental (Pentothal®, Abbott, Baar, 
Switzerland; 250 mg/kg i.p., 0.2 ml) immediately after the MRI acquisitions. The main left 
bronchus was immediately ligated to avoid collapse and the left lung was removed for 
histological analyses. The right lobes of the lung were used for qRT-PCR. 
Histology 
As described earlier [72], left lungs were immersed in 10% neutral buffered formalin for 24 h. 
Following fixation, lungs were trimmed, and three transverse slices were cut through the left 
lung (superior, median, and caudal parts) to include the main bronchi as well as the pulmonary 
alveoli. Sections were then dehydrated through increasing graded series of ethylic alcohol and 
embedded in one block of paraffin wax. Serial sections (3 µm) were stained with hematoxylin 
and eosin (H&E) to assess the general morphology, PAS for demonstrating excreted mucus 
and mucus-containing goblet cells, and 
picrosirius red for the identification of 
collagen fibers and newly synthesized 
collagen. 
Sections were analyzed by blinded to the 
treatment. The extent and the severity of 
parenchyma infiltration with 
inflammatory cells and fibrosis were 
analyzed using a scoring system adapted 
from the literature [128]. Severity scores 
were assigned to edema (perivascular, 
peribronchial, alveolar) and infiltration of 
inflammatory cells (perivascular, 
Figure 32: Quantification of picrosirius-stained histological slices 
of the lungs of mice, at day 14 after last administration of saline 
(A) or BLM (B). Areas corresponding to collagen accumulation 
were automatically recognized (yellow zones, lower panel). In 
these examples, the percentage of collagen areas were of 0.5 
and 7.0%, respectively for the saline and the BLM-treated 
mouse.  
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peribronchial, parenchymal), following the classification: none (score 0), slight (score 1), 
moderate (score 2), marked (score 3) and severe (score 4). The extent of the lesions was 
classified based on their percentage distribution as none (0%, score 0) focal (<25%, score 1), 
multifocal (26-50%, score 2) and diffuse (>51%, score 3). Abnormal histological features were 
recorded according to their extent and severity (total resultant score being the multiplication 
of severity and extent scores). Collagen was quantified using "Histolab" (Microvision 
Instruments, Evry, France). Picrosirius-stained slides were examined with a light microscope 
(Eclipse E600, Nikon, Egg, Switzerland) connected to a CCD progressive scan video color 
camera (XCD-U100 CR, Sony, Tokyo, Japan). The whole surface of the median slice of each lung 
section was captured at x10 magnification. The color corresponding to picrosirius was 
extracted by threshold setting and the area corresponding to picrosirius staining calculated 
(Figure 32). Results were expressed as percentage of picrosirius to the total lung surface. 
Immunohistochemistry was performed on paraffin sections using the following antibodies for 
detection of rabbit anti-ionized calcium-binding adapter molecule 1 (IBA-1) expressed by 
activated macrophages (019741, IBA-1 at 1/500, WAKO Chemicals, Neuss, Germany), goat 
anti-matrix metalloproteinase (MMP12), secreted by macrophages and involved in the 
breakdown of extracellular matrix (sc-8839, MMP12 at 1/50, Santa Cruz Biotechnology, 
Heidelberg, Germany), and rabbit anti-cluster of differentiation 3 (CD3) involved in T cells 
activation (RM9107S, CD3 at 1/40, Neomarkers, Thermo Fisher Scientific, Basel, Switzerland). 
The demonstration of these antibodies was carried out using the Ventana immuno-auto-
stainer Discovery XT (Ventana, Tucson, Arizona, US), according to programs Nr 69 (IBA1), 779 
(MMP12) and 811 (CD3).  
For quantification of IBA-1, MMP12 or CD3 on the histological sections, similar analyses were 
performed as described above for picrosirius determination. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
Removed lung tissue was stabilized in RNA later (Ambion, Zug, Switzerland; #AM7021,) and 
stored at -80°C until use. For RNA purification, samples were transferred to a 2 ml Eppendorf 
tube with 1000 µl of RLT buffer (Qiagen, Hombrechtikon, Switzerland; #79216) and β-
mercaptoethanol (Sigma-Aldrich, Buchs, Switzerland; #M3148 ) and one stainless bead 
(Qiagen, #69989). Samples were homogenized (Qiagen Tissue Lyser, #85300) in two to three 
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1-min runs at 30 rotations/s each, with 1 min on ice between the runs. After centrifugation 
for 3 min at 13 000 rpm, 4°C, 300 µl of the resulting supernatant were processed on the Rneasy 
Mini Kit (Qiagen, #74106 ) with a DNAse digestion step (Qiagen, #79254), accordingly to the 
manufacturer’s protocol. 
Resulting total RNAs were quantified on a NanodropTM system (Wilmington, DE, USA) and 1 
µg was reverse-transcribed using the high capacity cDNA RT kit (Applied Biosystems, Zug, 
Switzerland; #4368813). 
Expression of the different genes of interest was evaluated by real time PCR using the ABI 
Prism 7900HT system. Briefly, 10 ng/µl equivalent RNA per well was distributed in a 384 well 
plates (Applied Biosystems, #4326270), with 5 µl of the Taqman Universal Mastermix 2X kit 
(Applied Biosystems, #4324020) and 0.5 µl of 20X Assay-on-demand mix  Taqman probe 
(Applied Biosystem, #4331182). The different probes used and respective genes were: 
Mm00801666_g1 (Col1a1), Mm00483888_m1 (Col1a2), Mm00607939_s1 (Actinβ), 
Mm00802331_m1 (Col3a1), Mm00500554_m1 (Mmp12), Mm00441724_m1 (TGFb1), 
Mm01192933_g1 (CTGF), Mm00441818_m1 (Timp1), Mm99999056_m1 (MCP-1), 
Mm00443113_m1 (MCP-3), Mm99999057_m1 (MIP1-a). 
Expression for each sample was normalized to HPRT (Mm03024075 m1) and compared to the 
vehicle-treated group, using the 2-∆CT formula. The expression of HPRT was the same in all 
analyzed groups. 
Statistics 
Raw (baseline-unsubtracted) MRI data were analyzed using ANOVA with random effects 
(SYSTAT 12, Systat Software, Inc., San Jose, CA) to take into account the longitudinal structure 
of the data. For multiple comparisons a Bonferroni correction followed the ANOVA analysis. 
Histological and qRT-PCR data were analyzed using ANOVA comparisons (Student-Newman-
Keul’s method). Outliers identified by the Dixon’s test (mean±2xstandard deviation) were 
excluded from the statistical analyses. Mann-Whitney analyses (SYSTAT 11) were performed 
on histological scores. Significance was considered for p<0.05.   
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Results 
Body weight development 
The body weight development during the 
course of the study is summarized in Figure 
33. As body weight is an accepted indicator 
of the well-being of the mice during a 
challenge and an accurate abortion 
criterion, five and three BLM-challenged 
mice belonging respectively to the vehicle 
and the PT100 group were sacrificed before 
the end of the study (≥ 20% weight loss 
with respect to baseline body weight). Vehicle-treated mice were sacrificed at days 5, 7, 8, 
and 10 (two animals) after last BLM administration. In the PT100 group, animals were 
sacrificed at days 4, 7, and 8. Weight loss is a known effect of the antibiotic in small rodents 
[24]. 
Magnetic resonance imaging (MRI) 
Figure 34 shows axial MR images from BLM-challenged mice, treated with either vehicle or 
PT100. With the exception of signals from vessels (dotted arrows), the lung signal was low at 
baseline, due to the short T2* relaxation time of parenchymal tissue at 4.7 T [129]. 
Immediately after last BLM dosing (day 0), MRI revealed the presence of lesions throughout 
the lung (arrows), induced by the antibiotic. For each animal and time point, the total volume 
of these lesions was quantified from the MR images as described before. The volumes of 
lesions during the experimental period are shown individually in Figure 35A, while the average 
volumes for vehicle- or PT100-treated mice are summarized in Figure 35B. Animals were 
randomized at day 0 according to the BLM-elicited responses detected by MRI, in order to 
have similar average lesion volumes in the vehicle and the PT100 groups, at the beginning of 
compound treatment (day 1). 
Figure 33: Body weight (means±sem). The initial numbers of 
animals were 8 in the saline group and 12 in the BLM groups. 
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Histology of cellular infiltration and collagen deposition 
Histology at the end of the study revealed neither edema nor perivascular and peribronchial 
cellular infiltration in lung sections from naive and BLM-treated mice. Slight (score 1), focal 
(score 1) parenchymal cellular infiltration was detected in 4 out of 8 naive control animals. 
Moreover, focal to diffuse (scores 1 to 3) and moderate to severe (scores 2-4) parenchymal 
cellular infiltration was seen in BLM-treated mice. The total scores for parenchymal
Figure 34: Axial MR images of two mice challenged with BLM and treated with either vehicle (A) or PT100 (B) from day 1 to 
14. Day 0 corresponds to the time of last BLM dosing. For each animal, eight images covering the lung are shown per time 
point. Some lesions induced by BLM are indicated by white arrows. Images were acquired from spontaneously breathing 
animals. Neither cardiac nor respiratory gating was used.   
Figure 35: Pulmonary lesion volumes assessed from MR images in BLM-challenged mice. Treatment with compound (or 
vehicle) has begun at day 1, and continued until the end of the study. A) Individual values for each animal, at the different 
time points. B) Means±sem for the numbers of animals measured at every time point (indicated in parentheses). Following 
the acquisition at day 0, animals were randomized in order to have the same mean values in the PT100 and vehicle groups. 
### p<0.001 indicate Anova comparisons with respect to baseline values, while * p=0.04, ** 0.001<p<0.01, and *** p<0.001. 
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infiltration (multiplication of severity and extent 
scores) for animals that had received BLM and 
were treated with either vehicle or PT100 are 
summarized in Figure 36.  
The mean collagen content assessed in 
picrosirius-stained slices at day 14 after last 
vehicle or BLM challenge is summarized in Figure 
37A. Significant correlation was seen between 
the volumes of BLM-induced lesions detected in 
vivo by MRI and the collagen content determined 
histologically in the lungs of the same animals 
(Figure 37B). Both MRI and histological observations suggest a reduced BLM-induced response 
in the lungs of PT100 - compared to vehicle-treated mice. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
To determine the relative messenger RNA (mRNA) expression level of several markers in the 
lung fibrosis model, qRT-PCR on lung tissue was performed 14 days after the multiple 
administration of either saline or BLM. The following markers were chosen because of their  
Figure 36: Total histological scores (means±sem) for 
cellular infiltration comprising the multiplication of 
severity and extent scores for each mouse. Scores in the 
groups were compared using Mann-Whitney analyses. 
 
Figure 37: Quantification of collagen content in picrosirius-stained slices at day 14 after last saline or BLM administration. (a) Picrosirius 
areas reflecting collagen deposition are given as means (± sem) for the numbers of mice provided in parentheses. Levels of significance 
correspond to Anova comparisons (Student-Neuman-Keuls tests). (b) Correlations between the lesion volumes assessed in vivo by MRI 
and the collagen content determined in histological sections.  
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relationships to fibrosis development: collagen-1α1, -1α2, and -3α1, TGF-β1 (one of the                                                                                                                                                                                                                                                                                                                                                                                                                                          
main profibrogenic cytokines involved in the pathogenesis of lung fibrosis, which induces 
fibroblast differentiation into myofibroblasts and produce high levels of collagen), connective 
tissue growth factor (CTGF; widely thought to promote the development of fibrosis in 
collaboration with TGF-β; cooperative interactions between CTGF and TGF-β signaling are 
required to elicit overt tissue fibrosis); actin-β, MMP-12 (mice deficient in MMP-12 have 
reduced fibrosis in the model of interleukin-13 dependent pulmonary fibrosis induced by 
challenge with S. Mansoni eggs [130]), tissue inhibitor of metalloproteinases (TIMP-1; 
upregulated during fibrosis [131]), macrophage inflammatory protein (MIP)-1α, and 
Figure 38: Relative mRNA expression 
levels obtained via qRT-PCR analyses 
from lung tissue harvested at the end 
of the study (day 14 after last BLM or 
saline challenge). Values are provided 
as means±sem. Anova analyses were 
performed using Student-Newman-
Keuls tests. 
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monocyte chemotactic protein (MCP)-1 and -3. Significant differences were found in the actin-
β, MMP-12, MIP-1α, and MCP-3 mRNA expression levels in the lungs of PT100- compared to 
vehicle-treated mice (Figure 38). There were significant correlations between the relative 
mRNA expression levels of collagen-1α1 (R=0.8, p<0.001), -1α2 (R=0.75, p<0.001), -3α1 
(R=0.81, p<0.001) and histologically-determined collagen content (picrosirius staining). 
Histology of macrophages 
The reduced mRNA expression for MMP-12 [a marker of macrophages [132] and increased 
mRNA expression for MIP-1α and MCP-3 in the BLM/PT100 as compared to the BLM/vehicle 
group suggested an implication of macrophages in the mechanism of action of the compound. 
Immunohistochemical analyses at day 14 after last saline or BLM administration revealed that 
MMP-12 (a macrophage marker), IBA-1 (a macrophage activation marker) and CD3+ (a marker 
for T lymphocytes) were significantly increased in BLM- compared to saline-challenged mice 
(Figure 39). Moreover, IBA-1 was significantly increased in compound X-treated animals, 
suggesting an increased number of activated macrophages in this group. 
 
    
Discussion 
In the present work the effects of the FAP inhibitor, PT100, in the lungs of BLM-challenged 
C57BL/6 mice were assessed longitudinally with proton MRI. Measurements were performed 
on spontaneously breathing animals using a short echo time UTE sequence. No contrast agent 
Figure 39: Quantification of MMP-12, IBA-1 and CD3+ (means± sem) in histological slices at day 14 after last saline or BLM administration. 
Levels of significance correspond to ANOVA comparisons (Student-Neuman-Keuls tests). 
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was injected for the imaging procedure. At the end of the study, histological and qRT-PCR 
analyses were performed to further characterize the responses. 
In an earlier study concerning the same animal model, we had shown that BLM administered 
repeatedly in the nostrils of male C57BL/6 mice elicited a lasting response detected by MRI up 
to day 70 after dosing [70]. Histology revealed early fibrotic foci within the inflammatory areas 
at day 7 after repeated BLM dosing. This is consistent with evidence from the literature 
suggesting that the major fibro-proliferative phase induced by BLM in rats and mice occurs 
within the first week following its administration and that this process co-exists with 
inflammation. Histology also showed that from day 14 onwards fibrosis was the predominant 
component of the response elicited in the lungs of male mice by repeated BLM. Overall, those 
data indicated that repeated BLM administration leads to consistent and sustained fibrosis 
formation with moderate initial inflammation [70]. 
As evidenced longitudinally by MRI in the present study, the lesions induced by BLM in the 
lungs of vehicle-treated mice progressed over time. In contrast, the responses elicited by BLM 
did not progress in animals receiving PT100. Histology at the end of the study demonstrated 
significant less fibrosis in PT100- than in vehicle-treated, BLM-challenged mice. These 
observations suggest that PT100 administered therapeutically had an anti-fibro-proliferative 
effect. 
Significant differences in the actin-β, MMP-12, MIP-1α, and MCP-3 mRNA expression levels in 
the lungs of PT100- compared to vehicle-treated mice were revealed by qRT-PCR analyses. 
There were significant correlations between the relative mRNA expression levels of collagen-
1α1, -1α2, -3α1 and histologically-determined collagen content (picrosirius staining).  
Contrary to qRT-PCR, immunohistochemistry did not show differences in MMP-12 between 
the vehicle and PT100 treatment groups. Nonetheless, we consider these two approaches as 
equally informative and complementary. One reflects an average level of transcriptional 
activity for the gene of interest while the other addresses protein localization, with possible 
bias such as time lag for mRNA profiles to be translated into protein, or possible regulatory 
mechanisms at the translational level resulting in no protein. Therefore, follow up studies 
aiming at an in-depth characterization of the different molecular events and related kinetics 
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by microarray, western blotting and immunohistochemistry would result in a better 
understanding of the bleomycin induced lung injury model and PT100 effect.  
Of note, however, was the fact that the IBA-1 level determined histologically was higher in the 
lungs of PT100 - compared to vehicle-treated mice. Taken together, these observations 
suggest that therapeutic treatment with PT100 had an effect on the number of activated 
macrophages with no effect on the activation of fibroblasts. 
To date, several hundreds of compounds were identified in various models of experimental 
pulmonary fibrosis and proposed to have therapeutic potential for IPF [133]. However, only a 
small number have reached clinical trials and very few have been assessed in a therapeutic 
setting [133,134]. The vast majority of compounds that were examined in drug intervention 
studies in experimental pulmonary fibrosis are only successful in a preventive or prophylactic 
setting, which means they are given with or prior to administration of the fibrogenic stimulus 
[133]. Intervention studies in models of fibrosis could be more meaningful if the compound 
was administered in the fibrotic phase of the disease and not as prevention. As illustrated 
here, imaging may significantly support such studies, by enabling longitudinal assessments in 
the same animal. Moreover, randomization of animals at the beginning of treatment may 
assist drug testing, as BLM elicits rather variable responses in the lungs. 
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Introduction 
Pulmonary fibrosis is a lethal disease with often unknown cause (IPF) [21], characterized by 
fibroblast proliferation and extracellular remodeling (such as collagen and elastin deposition), 
thickening of alveolar walls, and infiltration of inflammatory cells [22-27]. Remodeling leads 
to an increased resistance of the lung tissue and therewith an increased compliance, which 
means a serious loss of organ function for the patients. To date no treatment against 
pulmonary is available and the limited numbers of in vivo readouts is challenging the 
pharmaceutical research.  
The availability of the bleomycin model of pulmonary fibrosis provides the opportunity to 
investigate in small rodents novel pharmacological approaches aiming to treat this crippling 
disease. Bleomycin is an antibiotic with activity against gram-negative bacteria [32] that 
possesses chemotherapeutic properties and is highly efficient in some types of carcinomas. In 
spite of these therapeutic characteristics, bleomycin may produce a dose-dependent 
pulmonary fibrosis in a significant portion of patients [21]. Therefore, single [33-35] or 
multiple [36] instillations of bleomycin is commonly used to induce experimental pulmonary 
fibrosis in small rodents. Application of the antibiotic causes an acute inflammatory reaction 
and fibrotic changes that resemble human fibrotic lung disease both histologically and 
physiologically [22,39].  
Somatostatin (sst) has been shown to be upregulated in human fibrotic lungs [135] and in the 
mouse bleoymycin model [136]. Thus, interest raised whether sst analogues may provide a 
potential therapy against pulmonary fibrosis. Indeed, a few sst analogues have shown 
antifibrotic activities in vitro and in vivo [137]. The somatostatin analogue, pasireotide 
(SOM230), binds to four out of five sst receptors (sst1, sst2A, sst3, and sst5) and is in use for 
treatment of Cushing’s disease. SOM230 attenuated pulmonary fibrosis in a mouse bleomycin 
model [136].  
Recently we reported the use of MRI to non-invasively follow the course of lung injury induced 
by repeated administration of bleomycin to mice [70,120], or of single or repeated bleomycin 
administration to rats [27]. In the present work this model of lung fibrosis has been used to 
investigate a therapeutic effect of SOM230 on established pulmonary fibrosis in rats.  The 
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responses in the lungs detected in vivo by MRI have been compared to post-mortem 
hydroxyproline and lung dry and wet weight determination. 
 
Material and Methods 
Ethics Statement 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(license number BS-2565). 
Animals 
Seven- to 9-week-old Sprague Dawley (SD) rats (n=69) (Elevage Janvier, Saint Berthevin, 
France) were used throughout the study. The presented data were collected in two 
independent studies (n=33 and n=36) with the same protocol regarding bleomycin challenge, 
SOM230 treatment, and necropsy. Animals were kept at an ambient temperature of 22 ± 2°C 
under a 12 h normal phase light-dark cycle and fed NAFAG® pellets (Nahr- und Futtermittel 
AG, Gossau, Switzerland). Drinking water and food were freely available. 
Oropharyngeal aspiration of bleomycin or saline  
Animals were lightly anesthetized with 3.5% isoflurane delivered in a box and bleomycin 
hydrochloride (3.0 mg/kg) in 100 µl of saline (0.9%) or vehicle (100 µl of saline (0.9%)) were 
administered via oropharyngeal aspiration (OA) using a micropipette. OA was performed as 
described by de Vooght et al. [68]. Rats were fixed on a surgery board, the tongue was pulled 
out with a forceps, and the liquid was placed onto the distal part of the oropharynx while the 
nose was gently closed.  
Injection of SOM230-LAR 
SOM230 in a long acting release (LAR) formulation (8 or 80mg/kg) was injected sub-
cutaneously (s.c.) in the neck of the animals, nine days after bleomycin challenge with an 
injection volume of 1 mL/kg for 8 mg/kg and 2 mL/kg for 80mg/kg administration. Rats were 
randomized into groups according to the bleomycin-induced responses detected by MRI at 
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day 8, in order to have the same mean lesion and lung volumes in all treatment groups at the 
beginning of compound dosing. 
Magnetic resonance imaging (MRI)  
During MRI signal acquisitions, animals were placed in prone position in a cradle made of 
Plexiglas. Body temperature was kept at 37±1°C using warm water flowing through the cradle. 
Following a short period of introduction in a box, anesthesia was maintained with 1.5-2% 
isoflurane in a mixture of O2/N2O (1:2), administered via a nose cone. All measurements were 
performed on spontaneously breathing animals; breathing rate was monitored and kept at 
approximately 60 breaths per minute. Averaging over several respiratory cycles suppressed 
artifacts caused by movements of the chest and the heart without the necessity of triggering 
the data acquisition [70,72]. As mentioned before, the presented data were collected in two 
independent studies using either a 47/40 or a Biospec 70/30 spectrometer (Bruker Medical 
Systems, Ettlingen, Germany) operating at 4.7 or 7.0 T, respectively. The operational software 
of the scanner was Paravision (Bruker). Two- and three-dimensional UTE sequences were used 
at 4.7 and 7.0 T, respectively. The following parameters were applied for the detection of 
bleomycin-induced lung injury and total lung volume in rats: 2D-UTE: TR 15.0 ms, TE 801 µs, 
604 projections, 2 averages, flip angle of the excitation pulse 25°, matrix size 192x192, slice 
thickness 1.5 mm and FOV 6.0 x 6.0 cm2. The total acquisition time was of 7.25 min for 24 
consecutive axial slices covering the entire lung. A birdcage resonator of 70 mm diameter was 
used for excitation and detection. 3D-UTE: TR 2.7 ms, TE 20 µs, 51360 projections, 5 averages, 
band width 64 kHz, flip angle of the excitation pulse 2°, matrix size 128x128x128, and FOV 5.0 
x 5.0 x 7.0 cm3. The total acquisition time was of 11.5 min for the FOV covering the entire lung. 
A birdcage resonator of 86 mm diameter was used for excitation and detection. 
MR image analysis – Volume of lung lesions 
At a given time point, the area of bleomycin-induced lesions was quantified on each image 
from the dataset covering the whole lung, using a semi-automatic segmentation procedure 
implemented in the IDL (Interactive Data Language Research Systems, Boulder, Colorado, 
USA) environment on a Linux system. Images were first low-pass-filtered with a Gaussian 
profile filter and then transformed into a set of four grey level classes using adaptive Lloyd-
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Max histogram quantitation. The highest class in the transformed images was extracted 
interactively by a region grower, whose border was drawn manually on each slice to control 
the growing and limit it to areas within the lung (Figure 12). For each image, the area thus 
segmented by region growing corresponded to high intensity signals in the lung. The total 
volume of high intensity signals was then calculated by adding the areas obtained for each 
image from the dataset, and multiplying the summed value by the slice thickness. 
Segmentation parameters were the same for all analyzed images.  
MR image analysis – Total Lung Volume 
To evaluate lung volumes (which is defined for 
this work as total volume of the lung, including 
tissue, air, and airways), regions of interest (ROI) 
have been manually drawn around the lung on 
each acquired slice using the software 
Paravision (Figure 40). The calculated areas of 
all ROIs for one animal have been added and 
multiplied by the slice thickness, resulting in 
the total lung volume.  
Post-mortem analyses 
Animals were sacrificed with an overdose of thiopental (Pentothal®, Abbott; 250 mg/kg (i.p.)) 
24 h after last MRI acquisition. The trachea and left bronchus were immediately ligated to 
avoid collapse of the lung. Following the organ’s removal, the left lobe was stored for later 
histological analyses, while the two right lobes were employed for the determination of 
hydroxyproline content. The other two right lobes were stored for later qRT-PCR analyses.  
Determination of hydroxyproline in lung tissue samples 
Lung tissue samples were weighed, dried in an oven at 90°C overnight, and the weight was 
recorded again. Dry tissues were then boiled in 0.5 mL of 6 M HCl at 120°C overnight (8-16 h) 
in Pyrex tubes with heat- and acid-resistant screw-on caps (article TES-830-70G; Fisher 
Scientific, Wohlen, Switzerland). After cooling down and adding 5 µL of phenolphthalein (1%), 
Figure 40: Evaluation of total lung volume. ROI (yellow 
line) was manually drawn around the lung on each 
acquired slice. 
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the samples were neutralized with NaOH 10 M (Sigma N°S-5881) and 6 M HCl. Black 
precipitate and brown color was removed by adding 100 µL of carbon suspension [10 mg/mL 
activated charcoal (article C4386; Sigma-Aldrich, Buchs, Switzerland) in water], centrifugation, 
and filtration. Five microliters of standard or hydrolyzed sample were pipetted in triplicate 
onto a 96 well plate, and 5 µL citrate acetate buffer (5% citric acid, 7.2% sodium acetate, 3.4% 
sodium hydroxide, 1.2% glacial acetic acid, distilled water) was added to each well, as well as 
100 µL of freshly prepared chloramine-T solution (14.1mg chloramine-T, 0.1mL n-propanol, 
0.1mL distilled water, 0.8mL citrate acetate buffer). The samples were then incubated at room 
temperature for 20 minutes. After adding 100 µL of Ehrlich’s reagent (2.5 g of 4-
(dimethylamino)benzaldehyde, 9.3 mL of n-propanol, and 3.9 mL of 70% perchloric acid), the 
wells were incubated for 20 minutes at 65°C. After cooling down, the samples were measured 
at 550 nm on a spectrophotometer (SpectraMax 340PC, Molecular Devices, Sunnyvale, CA, 
USA); a standard curve from 5 to 100 mg hydroxyproline in water was created. Data were 
expressed as µg/right lung lobe. 
Statistics 
For statistical analysis the software SigmaPlot™ (Systat Software Inc., San Jose, CA, USA) has 
been used. One-way ANOVA and Tukey tests have been performed for endpoint readouts 
while ANOVA with random effects and Tukey or Fisher tests have been used for readouts with 
multiple measurements to take into account the longitudinal structure of the data. The 
following abbreviations were used for the indication of significance: */#: 0.01<p<0.05; **/##: 
0.001≤ p ≤ 0.01 ***/ ###: p< 0.001. 
Results 
SOM230 reduced MRI-detected, bleomycin-induced lung injuries and total lung volume 
Oropharyngeal aspiration of 3mg/kg bleomycin in SD rats induced lung lesions, which could 
be detected by 2D and 3D UTE-MRI in two separate experiments (Figure 41 A-B). Starting at 
nine days after bleomycin challenge, two groups have been treated with either 8 or 80 mg/kg 
SOM230 LAR. Already one week after injection of SOM230, MRI signals significantly decreased 
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in both groups, compared to 
bleomycin-challenged animals 
without treatment. Note that the 
volumes of signals quantified 
using the 3D-UTE sequence were 
systematically higher than those 
quantified with 2D-UTE. This 
difference can be explained by a 
difference in sensitive between 
both approaches (see Discussion). 
Representative images of 
bleomycin- and saline-challenged 
lungs at day 8 (before begin of 
SOM230 treatment) and day 20 
(end of the study) are shown in 
Figure 42 and 43. The lesion 
volume, relative to the treatment 
begin (day 9, both studies 
combined) is shown in Figure 44. 
In this figure, relative signal 
volumes were provided because 
of the systematic differences in 
signal volumes due to differences 
in sensitivity between the 2D- and 
3D-UTE acquisitions. SOM230 
reduced, in a not dose-dependent 
way, bleomycin-induced lung 
injuries, while both control groups 
showed no changes in MRI lesion 
volume. 
Figure 41: MRI detected lung lesion volume in saline- and BLM treated 
rats, before and after SOM230 treatment in two separate experiments. A) 
Experiment 1: Lesion volume evaluated on images acquired by 2D-UTE. 
Number of animals were n=6 for saline and n=9 for all other groups. B) 
Experiment 2: Lesion volume evaluated on images acquired by 3D-UTE. 
Number of animals were n=9 all groups. . The statistical significance values 
***p<0.001 *p<0.5 indicate comparison to baseline 
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As discussed in Chapter 4.3 (“MRI-detected lung volume as a noninvasive readout for tissue 
deposition in the rat bleomycin model of pulmonary fibrosis”), MRI detected an increased 
total lung volume in the rat bleomycin model, with a correlation to wet and dry weight of the 
lungs. Since MRI-detected total lung volume reflects the effect of tissue deposition in the 
bleomycin model for pulmonary fibrosis (see chapter mentioned before), total lung volumes 
have been determined for all groups and time points and are presented in Figure 45. One week 
after bleomycin challenge, total lung volume was increased in all bleomycin groups, compared 
Figure 42: Representative images acquired by 2D-UTE 
MRI showing one animal per group at two different 
time points. Images on the left side have been 
acquired 8 days after BLM- or saline-challenge, before 
SOM230 treatment. Images on the right side have 
been acquired at the end of the study. Dotted arrows 
on the left side point to bleomycin-induced lesions. 
Arrows on the right side point to areas where lesions 
were resolved. 
 
 
 
Figure 43: Representative images acquired by 3D-UTE MRI 
showing one animal per group at two different time points. 
Images on the left side have been acquired 8 days after BLM- 
or saline-challenge, before SOM230 treatment. Images on 
the right side have been acquired at the end of the study. 
Dotted arrows on the left side point to bleomycin-induced 
lesions. Arrows on the right side point to areas where lesions 
were resolved. 
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to saline group. After injection of SOM230, lung volumes in both SOM230 groups stagnated 
and/or even slightly decreased, while the lung volumes of both control groups further 
increased between days 8 and 20. At the end of the study, two weeks after injection of 
SOM230, the lung volumes of rats treated with 8 or 80mg/kg SOM230 did not differ from 
those of saline-treated, healthy animals, while lung volumes in rats belonging to the bleomycin 
control group were still significantly increased, compared to all three other groups. 
 
SOM230 treated and bleomycin-challenged rats showed no difference in lung wet and dry 
weight compared to saline-group 
After the last MRI session, all animals have been sacrificed at day 21 after bleomycin- or saline-
challenge and two right lung lobes (caudal and cranial) have been weighed and dried for 
hydroxyproline determination. Wet and dry weight of these two lung lobes are presented in 
Figure 46. Bleomycin-challenged rats showed increased values of lung wet and dry weight, 
compared to all other groups. There was no significant difference observable between saline-
challenged and bleomycin/SOM230-treated animals, and no difference between the two 
SOM230 groups. The relative water content was 78.6-79.6% for all three groups with no 
significant difference. 
Figure 44 Effect of SOM230 on MRI-detected, BLM-
induced lung lesions. Data are presented relative to 
lung lesion volume eight days after challenge, before 
injection of SOM230. The statistical significance 
values ***p<0.001 indicate comparison to 
“Treatment start”. 
 
 
 
 
Figure 45: MRI detected total lung volume in saline- 
and BLM-treated rats, before and after SOM230 
treatment. A) Lung volume was evaluated on images 
acquired by 2D- and 3D UTE MRI. Number of animals 
was n=15 for saline and n=18 for all other groups.  
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 Correlation 
To confirm MRI-detected total lung volume 
as a readout for tissue deposition, 
correlation between lung volume and lung 
dry weight has been calculated (Figure 47). 
A strong correlation between the two 
readouts could be observed. 
 
Hydroxyproline content 
Hydroxyproline content of two right lung lobes was determined as described earlier, 21 days 
after saline- or BLM-challenge. BLM-challenged rats showed a significantly higher lung 
hydroxyproline content compared to saline group (Figure 48). Hydroxyproline content was 
also increased in the lungs of SOM230-treated animals, but the values of both SOM230 groups 
were slightly lower than in the BLM group (Figure 48). 
 
 
 
Figure 46 Wet weight (A) and dry weight (B) of two right lung lobes removed from SOM230- and untreated SD 
rats, 21 days after BLM- or saline-challenge. Number of animals was n=15 for saline- and n=18 for all BLM-groups. 
 
 
 
 
Figure 47 Correlation between MRI-detected total lung 
volume and dry weight of two lung lobes. Number of 
samples was n=69. 
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Discussion 
To date, only a small number of compounds, 
suggested to have antifibrotic effect on 
pulmonary fibrosis, have reached clinical trials 
[133,134]. Most of them have been assessed in 
preventive or prophylactic settings [133,134]. 
However, assessing the effects of on 
established fibrosis is more meaningful. In this 
work the therapeutic effect of SOM230, a 
somatostatin analogue, on bleomycin-induced 
pulmonary fibrosis has been investigated. MRI 
served as a non-invasive in vivo readout and 
was confirmed by several post-mortem 
analysis.  
The injection of two different doses of SOM230 LAR (8 and 80 mg/kg) led to a reduction of 
MRI-detected bleomycin-induced lung injuries in two independent studies. In the second 
study, baseline values and bleomycin-induced increase were slightly higher than in the first 
study. Since both studies were performed following exactly the same treatment protocol, the 
differences in absolute MRI signal values can be explained by use of two different MRI 
techniques. For the second study a 7.0 T magnet has been used and a 3D UTE sequence was 
applied. Since this sequence allows the detection of a 3D volume without slice selection, more 
signal, especially from the lung parenchyma, could be detected compared to the 2D 
acquisition (for comparison between images acquired by 2D- and 3D-UTE see Figures 42 and 
43). Moreover, a significantly shorter TE was obtained using the 3D-UTE sequence (20 µs 
compared to 800 µs in the 2D-UTE sequence), which also contributed to the enhanced 
sensitivity. Nonetheless, in both studies SOM230 significantly reduced the detected injuries, 
relative to treatment start, in a comparable manner.  
Additionally to lung lesion volume, total lung volume has been evaluated. SOM230 stopped 
the bleomycin-induced increase of MRI-detected total lung volume in such a way that, at the 
end of the study, no difference was found between the saline and both SOM230 groups. The 
Figure 48 Hydroxyproline content in two right lung lobes 
of un- and SOM230-treated SD rats, 21 days after saline- 
or bleomycin-challenge. For statistical analysis, one-way 
ANOVA and Fisher-Test have been applied. 
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results of lung wet weight, dry weight confirmed that observation. No differences between 
the BLM/SOM230- and saline-treated animals could be observed, while the values in the BLM-
challenged control group were significantly increased. The presence of lung edema may be 
excluded, since the relative water content of the lungs was in the same range, in all four 
groups. SOM230 slightly decreased the lung hydroxyproline content, compared to BLM group, 
but the values of both SOM230 groups were still significantly higher than in the saline group. 
These data let suggest, that hydroxyproline that has been deposited during the first nine days, 
before begin of SOM230 treatment, could not completely be removed. 
Overall, the presented data let suggest that SOM230 reduced the bleomycin-induced tissue 
deposition, in a not dose-dependent manner. Twenty and one days after injection of SOM230, 
no readout, except hydroxyproline, showed a difference between saline- and BLM/SOM230-
treated animals. The question whether SOM230 actually healed bleomycin-induced lung 
fibrosis, has to be answered by histological analysis. As discussed earlier (see chapter “MRI-
detected lung volume as a noninvasive readout for tissue deposition in the rat bleomycin 
model of pulmonary fibrosis”), the bleomycin-induced increase in total lung volume reflects a 
change in lung mechanics. The fact that the lung volumes in bleomycin-challenged rats treated 
with SOM230 were decreased, compared to control groups, suggests that the sst analogue 
may have a positive impact on the lung function. 
Since SOM230’s mechanism of action is not completely understood, further analyses have to 
be performed. Gene expression of Col1α1, Col3α1, TGF-β, TNF-α and all five sstr will be 
determined in lung tissue samples and several biomarkers for inflammation and fibrosis will 
be measured in blood serum and plasma, taken before the euthanasia of the animals at the 
end of the study. 
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6) Imaging of Renal Fibrosis by MRI: Perfusion, Renal Clearance, and 
Macrophage Visualization 
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Introduction 
Adriamycin (doxorubicin, Pfizer) is licensed for the treatment of different cancers, such as 
breast cancer, lung cancer, and ovarian cancer. The medication works by binding to DNA in 
cells, altering the shape of the DNA and killing the cells. While adriamycin can kill healthy and 
cancerous cells, it has a greater effect on cancerous cells because they multiply more rapidly. 
Adriamycin is a well-known inducer of renal injury in rodents, which mirrors that seen in 
human chronic kidney disease due to primary focal segmental glomerulosclerosis [45-47]. 
Adriamycin-induced nephropathy has enabled a greater understanding of the processes 
underlying the progression of chronic proteinuric renal disease [48,49]. The model is 
characterized by podocyte injury followed by glomerulosclerosis, tubulointerstitial 
inflammation and fibrosis. Adriamycin-induced renal injury has been shown in numerous 
studies to be modulated by both non-immune and immune factors, thus facilitating 
mechanistic studies of tubulointerstitial injury [47,138].  
In the present work, MRI techniques have been used to non-invasively characterize kidney 
anatomy and function in a rat model of adriamycin-induced nephropathy. Renal function has 
been analyzed with a dynamic contrast enhanced (DCE) technique as reported earlier by 
Baumann and Rudin [139] and Laurent et al. [140]. The approach is based on the fact that Gd 
chelates are small particles similar to inulin that are first disseminated to the vascular space 
after the intra-venous (i.v.) administration and then pass through the extracellular space and 
are freely filtered from the glomeruli. Kidney perfusion was assessed by the i.v. injection of an 
extravascular, SPIO contrast agent. As SPIO nanoparticles are removed from the circulation by 
cells from the mononuclear phagocyte system via adsorptive endocytosis [141] in a process 
mediated by the monocyte integrin Mac-1 receptor [142], anatomical images were acquired 
24 h after SPIO administration with the aim of detecting the infiltration of macrophages into 
diseased kidneys. This property of SPIO nanoparticles has been exploited extensively to track 
in vivo by MRI macrophage infiltration into inflamed areas in several disease areas, ranging 
from atherosclerosis, stroke and myocardial infarction to solid organ transplantation (see 
[143,144] for reviews). Finally, in addition to MRI evaluations, the glomerular filtration rate 
(GFR) has been assessed biochemically, and histological as well as hydroxyproline analyses 
have been performed at the end of the study. 
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It has been demonstrated earlier that 1D11, in particular in combination with angiotensin II 
blockade, had antifibrotic effects in models of glomerulonephritis [42,145,146]. In those 
studies, the antibody was administered preventatively, before onset on injury. In this study, 
1D11 has been administered after the induction of nephropathy to investigate a potential 
therapeutic effect of the antibody. 
Materials and Methods 
Experiments were carried out with the approval of the Veterinary Authority of the City of Basel 
(license BS-2353). 
Animals 
Male Wistar rats (n=26) (Elevage Janvier, Saint Berthevin, France) weighing approximately 270 
g at the beginning of the study were used. Animals were kept at an ambient temperature of 
22 ± 2°C under a 12 h normal phase light-dark cycle and fed NAFAG® pellets (Nahr- und 
Futtermittel AG, Gossau, Switzerland). Drinking water and food were freely available. Three 
groups of rats were analyzed: 
Group 1: saline-challenged rats (control group) (n=6) 
Group 2: adriamycin-challenged, vehicle-treated rats (n=10 at the beginning of the study) 
Group 3: adriamycin-challenged, 1D11-treated rats (n=10 at the beginning of the study) 
Adriamycin administration 
Rats were anesthetized with 2.0% isoflurane (Abbott, Cham, Switzerland) delivered through a 
nose cone and adriamycin (4 mg/kg; doxorubicin hydrochloride, Sigma-Aldrich, Buchs, 
Switzerland) or vehicle (2 ml/kg of saline (0.9%)) was administered intravenously into the tail. 
Animals were allowed to recover immediately afterwards. 
Compound administration 
Adriamycin-challenged rats were dosed i.p. once a week with vehicle (saline) or the TGFβ1,2,3 
antibody, 1D11 (2 mg/kg; R&D Systems, Minneapolis, MN), starting on day 7 after adriamycin. 
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Biochemical analysis 
Blood biochemistry 
Blood was taken from the sublingual vein into edetic acid–coated tubes for monitoring 
hematologic values by using a counter (Technicon H*1E; Bayer, Zurich, Switzerland). Blood 
was also collected in heparin-coated Eppendorf tubes and centrifuged for 3 minutes at 13 000 
rpm in an Eppendorf tabletop centrifuge (Biofuge; Brinkmann Instruments, Westbury, NY). 
The resulting supernatant was biochemically analyzed for determination of creatinine by using 
a Synchron CX5 instrument (Beckman Coulter, Fullerton, CA). 
Glomerular filtration rate (GFR) 
GFR was determined by multiplying the ratio of creatinine in urine and in blood serum by the 
amount of urine secreted per hour. Urine secretion was assessed by placing the animals in 
individual metabolic cages in which the bottom was permeable. During the stay in the 
metabolic cages (24 h), animals had access to food and water provided and their consumption 
was measured. Urine was collected in Plexiglas tubes cooled with ice water, the day before an 
MRI examination. The creatinine and total protein content in the urine were assessed by using 
a Synchron CX5 instrument. 
Magnetic resonance imaging (MRI) 
Experiments were performed on a 4.7-T Bruker Biospec MRI system (Bruker Biospin, Ettlingen, 
Germany) equipped with a self-shielded 12-cm bore gradient system capable of switching 200 
mT/m in 170 μsec. The operational software of the scanner was Paravision (Bruker). A proton 
birdcage resonator with diameters of 72 mm (Bruker Biospin) was used for radiofrequency 
excitation and detection. During MRI signal acquisitions, animals were placed in supine 
position in a cradle made of Plexiglas. Body temperature was kept at 37±1°C using a heating 
pad. Following a short period of introduction in a box, anesthesia was maintained with 2% in 
a mixture of O2/N2O (1:2), administered via a nose cone. All measurements were performed 
on spontaneously breathing animals; neither cardiac nor respiratory triggering was applied. 
After placing a rat in the magnet, scout fast images were acquired for localization purposes. 
Dynamic acquisitions of the kidney in conjunction with the i.v. administration of a 
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paramagnetic contrast agent were then followed by perfusion analyses using an intravascular 
agent containing SPIO nanoparticles. As SPIO is taken up by monocytes in the blood stream, 
further MRI acquisitions aiming at assessing macrophage infiltration into the kidney were 
performed 24 h later. Animals were fully recovered from anesthesia about 10 min after the 
end of an imaging session. 
Dynamic contrast enhanced (DCE) MRI of the kidney 
The acquisition of functional data was performed using a gradient-echo sequence with the 
following parameters: TR 10.6 ms, TE 2.2 ms, bandwidth 200 kHz, FOV 70x60 mm2, matrix 
128x72, slice thickness 1.5 mm, number of averages 4, flip angle of the radiofrequency 
excitation 25°. The position of the slice was chosen to have both the right and the left kidneys 
well delineated. The acquisition time for one image was of 3.05 s. In one session, 170 images 
of the same slice were acquired sequentially. Following the acquisition of 15 baseline images, 
a paramagnetic contrast agent (Gd-DOTA, Dotarem, Guerbet, Rossy, France; 20 µL/100 g body 
weight) approved for clinical use was administered intravenously as a bolus and then flushed 
with 0.3 mL of saline within 2 s. This procedure is based on the fact that Gd-DOTA is excreted 
though the kidneys [147-149]. 
Perfusion 
Perfusion measurements were performed using a gradient-echo sequence with the following 
parameters: TR 8.7 ms, TE 3.8 ms, bandwidth 100 kHz, flip angle of the excitation pulse 10°, 
FOV 70x60 mm2, matrix 128x64, slice thickness 1.5 mm. The acquisition time for one image 
was 560 ms. Eighty images were acquired consecutively at the same anatomical location. After 
the 10th image, 500 µL/kg body weight of SPIO particles (Endorem, Guerbet; 11.2 mg Fe/mL, 
nanoparticles having a diameter on the order of 150 nm) were injected into the tail vein for   
1 s. 
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Anatomy 
Anatomical images were acquired using a gradient-echo sequence with the parameters: TR 
22.6 ms, TE 8.4 ms, bandwidth 29.8 kHz, flip angle of the excitation pulse 10°, FOV 60x60 mm2, 
matrix size 128x128, slice thickness 1.5 mm, and number of averages 20, fat suppression, 
resulting in a measurement time of 57.9 s per image. A single slice image was obtained by 
interpolating the dataset to 256x256 pixels. Five contiguous slices were acquired sequentially 
per imaging session. 
MR image analysis 
Kidney function via DCE MRI 
Following the bolus injection of the contrast agent, MRI monitored the passage of the contrast 
agent through the renal system in a time-resolved manner, thus yielding a measure for the 
kidney function. Functional information was derived by analyzing the mean signal intensities 
for regions-of-interest (ROIs) in the outer strip of the outer medulla, for each of the 170 images 
comprising one functional data set. Position, shape, and size of the ROIs were carefully chosen 
in order to ensure that they covered approximately the same region, despite movements of 
the kidney caused by respiration. 
From the time-dependent signal intensity curves specific to each kidney region, the local Gd-
DOTA concentration ([Gd-DOTA]) was assessed using the procedure described in detail in 
[139,140,150]. This procedure is based on the fact that Gd-DOTA is predominantly excreted 
though the kidneys [147-149] without tubular secretion or reabsorption [147]; thus, the main 
route of its elimination is glomerular filtration. Time-course changes in signal intensities were 
translated into local Gd-DOTA concentrations assuming a linear dependence with signal 
enhancement, as described previously [139,140].  
For each animal, the mean of the Gd-DOTA concentrations in the left and right kidneys was 
obtained for the outer stripe of the outer medulla in a time-resolved manner, from the signal 
changes induced by the contrast agent in the MR images. From this [Gd-DOTA] profile, the 
tracer washout rate (TWR, in mmol/min) has been determined by calculating the rate with 
which the concentration decreased over time. 
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Perfusion analysis 
The superparamagnetic contrast agent induced local changes in susceptibility that resulted in 
a signal attenuation proportional to the perfusion of the kidney. For a series of images, signal 
intensities were assessed on ROIs located in the cortex/outer stripe of outer medulla. Position, 
shape, and size of the ROIs were carefully chosen in order to ensure that they covered 
approximately the same region, despite movements of the kidney caused by respiration. The 
mean signal intensities for the pre-injection images provided baseline intensities, S(0). 
Perfusion indexes were determined from the mean values of the ratios [151] -ln[S(t)/S(0)] ~ 
TE.V.cT (t) where TE is the echo time, V the blood volume, and cT the concentration of contrast 
agent, over five images following injection of the superparamagnetic contrast agent. 
Anatomical analysis 
Signal intensities were assessed on ROIs located in the cortex/outer stripe of outer medulla. 
Position, shape, and size of the ROIs were carefully chosen in order to ensure that they 
covered approximately the same anatomical region. The signal in the kidney was normalized 
to signal in the muscle. An average signal intensity was calculated over the five anatomical 
images acquired for every animal at each imaging session. 
Post-mortem analyses 
At the end of the study, rats were sacrificed with an overdose of CO2 immediately after an MRI 
acquisition. Following the organ’s removal, the left kidney was used for histological analyses, 
while the right kidney was used for hydroxyproline analyses. 
Histology 
Histological analysis was performed in a blind manner as described in more detail earlier 
[152,153]. Kidneys were harvested and fixed with 10% neutral phosphate-buffered formalin, 
pH 7.4, for 48 h. After fixation of the tissue, dehydration through increasing graded series of 
ethylic alcohol (50%, 70%, 80%, and 100%) and embedding in paraffin wax, six serial 3-µm 
sections were cut longitudinally through the kidneys, so as to include cortical and medullary 
tissue as well as renal papilla, and six different stainings were applied: H&E to assess the 
general morphology; PAS reaction for the demonstration of basal membranes and 
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carbohydrates, in order to evaluate the extent of glomerulosclerosis and tubular infiltration; 
picrosirius red for the demonstration and the quantification of collagen (fibrosis); AFOG for 
the demonstration of glomerular protein deposits; Perls’reaction for the demonstration of 
iron in the kidney; and ED1 immunohistochemistry for the detection of macrophages in the 
kidney.  
Assessment and scoring of abnormal histological features 
Following features were scored: interstitial changes, tubulopathy, and glomerulopathy. 
Interstitial changes: infiltration of the renal parenchyma with mononuclear cells. Cellular 
infiltration was assessed on the whole transverse kidney section as follows [154]: 0 = none; 1 
= occasional infiltrates surrounding glomeruli and blood vessels; 2 = multiple infiltrates 
surrounding glomeruli and blood vessels; 3 = severe infiltration accompanied by peritubular 
infiltration and interstitial fibrosis 
Tubulopathy: tubulitis, sclerotic tubules, distended tubules and hyaline casts. Five hundred 
tubules were counted per section and the number of either infiltrated, sclerotic, distended or 
hyaline cast content tubules was expressed as a percentage of the total number of tubules per 
section 
Glomerulopathy: PAS positive deposits, mesangial expansion, enlarged capillary lumen and 
thickening of the basal membrane. One hundred glomeruli were counted per section and the 
number of abnormal glomeruli was expressed as a percentage of the total number of 
glomeruli analyzed per section. 
Tubulopathy and glomerulopathy were scored semi quantitatively on a scale (0 to 3) derived 
from the Banff scoring for chronic rejection [155] as follows: 1 = less than 25% of abnormal 
features; 2 = 26 to 50% of abnormal features; 3 = more than 51% of abnormal features. 
Assessment and scoring of ED1 infiltration 
Immunohistochemistry labeling for ED1 positive macrophages was done on each kidney 
section and the quantification performed as follows: 
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Glomeruli: One hundred glomeruli were observed per section and the number of glomeruli 
infiltrated with at least one ED1 positive cell was counted. Results were expressed as a 
percentage of positive ED1 glomeruli. 
Interstitium: ED1 positive staining was quantified using the image analysis software "Spectrum 
Plus" (Aperio, Nikon, Egg, Switzerland). ED1 labeled slides were scanned with SanScope 
(Aperio) at x40 magnification. The whole surface of each kidney section was manually 
delineated and the color corresponding to the ED1 was extracted by threshold setting. The 
ED1area within the delineated region was automatically calculated. Values were recorded as 
a percentage of ED1 of the total measured area. 
For each animal, a nephropathy score was calculated by adding the glomerulopathy score, the 
score for mononuclear infiltration into the interstitium, and the tubular score. 
Quantification of iron 
Sections were stained applying Perl’s Prussian blue reaction to demonstrate ferric iron in 
tissue. The percentage of iron was determined using a classical black/white digitization. Two 
representative areas of 280,000 µm2 each were chosen in the cortex and results are presented 
as means of the two values assessed per kidney. 
Quantification of collagen 
Sections (3 µm) were stained with picrosirius red for the identification of collagen fibers and 
newly synthesized collagen. As described earlier for analyses of pulmonary fibrosis [27,70], 
collagen was quantified using the program "Histolab" (Microvision Instruments, Evry, France). 
Picrosirius-stained slides were examined with a light microscope (Eclipse E600, Nikon) 
connected to a CCD progressive scan video color camera (XCD-U100 CR, Sony, Tokyo, Japan). 
One third of the surface of each kidney section was captured at x10 magnification and the 
color corresponding to picrosirius red was extracted by threshold setting and the all collagen 
area automatically calculated. Values were recorded as a percentage of picrosirius of the total 
measured area. 
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Determination of hydroxyproline in kidney tissue samples 
Hydroxyproline assessments in kidney tissue were performed using analogous procedures 
described earlier for the lung [120]. Kidney tissue samples were weighed, dried in an oven at 
90°C overnight, and the weight was recorded again. Dry tissues were then boiled in 0.5 mL of 
6 M HCl at 120°C overnight (8-16 hours) in Pyrex tubes with heat- and acid-resistant screw-on 
caps (article TES-830-70G; Fisher Scientific, Wohlen, Switzerland). After cooling down and 
adding 5 µL of phenolphthalein (1%), the samples were neutralized with NaOH 10 M (Sigma 
N°S-5881) and 6 M HCl. Black precipitate and brown color was removed by adding 100 µL of 
carbon suspension [10 mg/mL activated charcoal (article C4386; Sigma-Aldrich, Buchs, 
Switzerland) in water], centrifugation, and filtration. Five microliters of standard or hydrolyzed 
sample were pipetted in triplicate onto a 96 well plate, and 5 µL citrate acetate buffer (5% 
citric acid, 7.2% sodium acetate, 3.4% sodium hydroxide, 1.2% glacial acetic acid, distilled 
water) was added to each well, as well as 100 µL of freshly prepared chloramine-T solution 
(14.1 mg chloramine-T, 0.1mL n-propanol, 0.1mL distilled water, 0.8mL citrate acetate buffer). 
The samples were then incubated at room temperature for 20 minutes. After adding 100 µL 
of Ehrlich’s reagent (2.5 g of 4-(dimethylamino)benzaldehyde, 9.3 mL of n-propanol, and 3.9 
mL of 70% perchloric acid), the wells were incubated for 20 minutes at 65°C. After cooling 
down, the samples were measured at 550 nm on a spectrophotometer (SpectraMax 340PC, 
Molecular Devices, Sunnyvale, CA, USA); a standard curve from 5 to 100 mg hydroxyproline in 
water was created. Data were expressed as µg/kidney. 
Statistics 
For statistical analysis the software SYSTAT 13 (Systat Software, Inc., San Jose, CA) has been 
used. GFR, biochemical and MRI data were analyzed employing ANOVA with random effects 
(SYSTAT 12, Systat Software, Inc., San Jose, CA) to take into account the longitudinal structure 
of the data. Histological data were analyzed with Anova. Kruskal-Wallis tests were used to 
compare histological scores. RT-PCR results were analyzed with t-tests. Statistical significance 
was assumed at the level p<0.05. 
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Results 
Because of necrosis in the tail around the site of injection, one animal in the adriamycin group 
and three rats in the adriamycin plus 1D11 group had to be sacrificed prematurely, around ten 
days after injection. 
GFR and biochemical markers 
Figure 49A summarizes the GFR determined for saline and adriamycin-treated rats, derived 
from the ratio of creatinine in urine and blood, multiplied by the amount of urine secreted per 
hour. Protein in urine is shown in Figure 49B. 
DCE-MRI  
Figure 50A shows representative profiles of [Gd-DOTA], calculated from signal changes 
evaluated in the outer stripe of the outer medulla. From such profiles, it becomes evident 
that, in adriamycin-treated rats, the course of contrast material in the kidney differed 
significantly from that in saline-treated rats, both concerning the time point of maximum 
concentration, and the maximum concentration itself. The TWR, assessed from such 
concentration profiles (Figure 50B), is summarized in Figure 50C for the different treatment 
groups. The data suggest that the kidney function was already impaired at week 2 after 
adriamycin administration. 
Figure 49: Biochemical assessments in blood and urine. A) GFR (means±sem) and B) protein in urine (means±sem) for saline 
and adriamycin-treated rats. The levels of significance reflect comparisons using Anova with random effects (those levels 
indicated above the bars correspond to comparisons with the baseline values, in the same group). Although not indicated 
explicitly, the protein values for adriamycin-challenged animals were significantly higher (p<0.001) compared to saline 
controls at all time points, except at baseline. 
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 Perfusion MRI 
Figure 51 summarizes the perfusion indices 
assessed at different time points after saline 
or adriamycin injection, for the different 
groups of animals. The data reveal that, for 
adriamycin-treated rats, kidney perfusion 
was reduced during the course of the 
experiment. 
 
 
Figure 51: Perfusion index (means±sem) derived using a bolus 
tracking method, with injection of a SPIO contrast agent 
(Endorem). The levels of significance reflect comparisons using 
Anova with random effects (the levels indicated above the 
bars correspond to comparisons with the baseline values, in 
the same group).  
 
Figure 50:  Analyses of DCE MRI experiments. A) Time profiles of Gd-DOTA concentration ([Gd-DOTA]) in the outer stripe 
of the outer medulla for three rats (one challenged with saline, the other challenged with adriamycin, and the third 
challenged with adriamycin and treated with 1D11). The profiles correspond to DCE MRI measurements at 2, 4 and 6 
weeks after administration of saline or adriamycin. B) Time profile of Gd-DOTA concentration in the outer stripe of the 
outer medulla at baseline. The tracer washout rate (TWR) was calculated from the clearance of the contrast agent in the 
analyzed ROI. C) TWR in the outer stripe of the outer medulla (means±sem) for saline and adriamycin-treated rats. The 
levels of significance reflect comparisons using Anova with random effects (those levels indicated above the bars 
correspond to comparisons with the baseline values, in the same group). 
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Anatomical MRI 
Starting week 4 after adriamycin challenge, signal attenuation was observed in the kidney 
cortex/outer medulla in anatomical images acquired 24 h after Endorem injection (Figure 52 
and 53A). For saline-challenged rats, signal intensity remained unchanged during the 
experimental period.   
Histology - Macrophage infiltration 
Analysis of Prussian blue-stained 
histological sections revealed moreover 
that iron was present only in 
macrophages (Figure 53B). At the 
interstitial level, histology revealed an 
infiltration of the renal parenchyma with 
mononuclear cells among which the 
majority was macrophages expressing 
ED1 (Figure 53C-D). At week 6 after 
adriamycin injection, highly significant 
negative correlations were found 
between the relative MRI signal intensity 
in the kidney in anatomical images 
acquired 24 h following SPIO 
administration, and the histological 
quantification of iron (R=-0.74, p=2.6x10-
4) and ED1 (R=-0.76, p=7.0x10-5) (Figure 
53 E-F).  
Nephropathy 
The main features of nephropathy induced by adriamycin at 6 weeks after administration of 
the antibiotic were:  
(a) at the glomeruli level: mainly deposits of PAS positive material, enlargement of capillary 
lumen, thickening of the basal membrane with rare mesangial expansion. These abnormal 
Figure 52: Assessment of macrophage infiltration by MRI. 
MR images acquired from three rats at baseline and 2, 4, and 
6 weeks after injection of saline or adriamycin. Animals that 
had received adriamycin were treated with either vehicle or 
1D11. At each time point, acquisitions took place 24 h after 
Endorem administration. Starting at week 4, prominent 
signal decrease in the cortex/outer medulla can be noted for 
adriamycin-challenged rats (arrows). 
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Figure 53: Assessment of macrophage infiltration by MRI and histology. A) Signal intensity in the cortex/outer medulla 
normalized to that in the muscle (means±sem). The levels of significance reflect comparisons using Anova with random 
effects (the levels indicated above the bars correspond to comparisons with the baseline values, in the same group). B) 
Percentile iron content in the histological sections (means±sem). The levels of significance reflect Anova comparisons. 
C) ED1 score on histological slices from the left kidneys at week 6. The significance levels p refer to Kruskal-Wallis 
comparisons between the groups. The numbers in parenthesis indicate how many animals received a given score. D) 
Percentile ED1 area (means±sem). The levels of significance correspond to Anova comparisons between the groups. E) 
Correlation between iron content and the relative MRI signal intensity in the kidney cortex/outer medulla. F) Correlation 
between ED1 staining and the relative MRI signal intensity in the kidney cortex/outer medulla. R stands for the Pearson’s 
correlation factor.  
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characteristics were named glomerulopathy. The histological observations are summarized in 
Figure 54A; (b) at the tubular level: mainly sclerotic tubules with atrophy of the epithelial cells, 
distended tubules, hyaline casts and rare tubulitis (tubules infiltrated with inflammatory cells).  
Figure 54 B summarizes the histological observations of kidney sections concerning tubuli. The 
total nephropathy scores, comprising the sum of the glomerular and tubular scores, are 
presented in Figure 54C. 
 
Fibrosis 
The overall quantification of picrosirius demonstrated a doubling in collagen content in the 
kidneys of rats that received adriamycin. Treatment with 1D11 had no influence on collagen 
(Figure 55A).  
Figure 54: Histology of glomeruli, tubuli and nephropathy at week 6. A) Left: Total glomerular score. The significance 
levels p refer to Kruskal-Wallis comparisons between the groups. The numbers in parenthesis indicate how many 
animals received a given score. Right: Percentile glomerulopathy (means±sem). The levels of significance correspond 
to Anova comparisons between the groups. B) Left: Total tubular score. The significance levels p refer to Kruskal-Wallis 
comparisons between the groups. The numbers in parenthesis indicate how many animals received a given score. Right: 
Percentile tubulopathy (means±sem). The levels of significance correspond to Anova comparisons between the groups. 
C) Nephropathy scores calculated by adding the glomerulopathy scores, the scores for mononuclear infiltration into 
the interstitium, and the tubular scores. The significance levels p refer to Kruskal-Wallis comparisons between the 
groups. The numbers in parenthesis indicate how many animals received a given score.  
 
104 
 
 
Hydroxyproline assessments 
A modest increase in hydroxyproline was 
found in the kidneys of adriamycin-
challenged rats, consistent with the 
formation of fibrosis in the model (Figure 
55B). 
Discussion 
Histological analysis is a cornerstone for 
studying mechanisms of renal disease. 
However, analysis in human disease is limited 
by a relative paucity of tissue availability. 
Renal biopsies are only pursued if a 
presumptive diagnosis cannot be established 
on clinical grounds. Similarly to the situation 
of human studies, biopsies in animals are 
usually limited to one time point, because of 
their invasive nature. Tissue sampling is thus 
typically restricted to the time of disease 
presentation and is rarely performed in 
follow-up, providing a mere snapshot of 
disease course. In view of the limitations of 
invasive methods to study renal disease, we aimed at verifying here the suitability of MRI to 
longitudinally follow the course of adriamycin-induced kidney nephropathy in rats. Both 
anatomical and functional readouts were characterized.  
A single intravenous injection of adriamycin leads to proteinuria and progressive renal disease, 
with the onset of proteinuria occurring within 5–7 days of exposure [156-158]. This is 
accompanied by a progressive reduction in glomerular filtration rate, as measured by 
increased serum creatinine and/or blood urea nitrogen [156,159-161]. In the present work, 
proteinuria was present throughout the study (Figure 49B). Compared to baseline values 
within the same group of animals, serum creatinine levels increased after adriamycin injection 
Figure 55:. Fibrosis assessment at week 6 by histological 
and hydroxyproline analyses. A) Percentile picrosirius area 
on histological slices from left kidneys. Values are 
presented as means±sem. The levels of significance 
correspond to Anova comparisons between the groups. B) 
Hydroxyproline values (means±sem) in the right kidneys. 
The levels of significance reflect Anova comparisons. 
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(data not shown). However, differences in serum creatinine levels at baseline hampered a 
clear differentiation between the experimental groups: only at week 6 was the serum 
creatinine level significantly higher in adriamycin-treated animals compared to saline-
challenged rats. GFR determined through biochemical analyses of urine and blood (Figure 49A) 
was tendentially reduced in the adriamycin groups. In contrast, through the clearance studies 
of Gd-DOTA, DCE MRI clearly revealed an impaired kidney function as the tracer washout rate 
(TWR) was significantly reduced at all time points after adriamycin (Figure 50C). These results 
indicate that MRI is significantly more sensitive than the biochemical analyses of urine and 
blood to reveal the impairment of kidney function elicited by adriamycin.   
Histological analysis performed at the end of the study revealed glomerulopathy (Figure 54A), 
sclerotic tubules with atrophy of the epithelial cells and distended tubules (Figure 54B), 
fibrosis (Figure 55A), and macrophage infiltration into the renal parenchyma (Figure 53 B-D) 
in kidneys of adriamycin-challenged rats. The nephropathy scores, corresponding to the sum 
of glomerulopathy, mononuclear infiltration, and tubular scores, were significantly increased 
in adriamycin-treated kidneys (Figure 54C). The increase in hydroxyproline (Figure 55B) found 
in the kidneys of adriamycin-challenged rats was consistent with the formation of fibrosis in 
the model. Overall, these changes reflect features of the adriamycin model in rats [46,47,156]. 
The decrease of kidney perfusion detected by MRI in adriamycin-challenged rats (Figure 51) 
was consistent with progressive renal diseases being associated with both a progressive loss 
of vascular structures [162-165] and an excess of vasoconstrictor substances such as 
angiotensin-II and endothelin-1 [166,167], both of which may decrease oxygen supply to the 
renal parenchyma. Moreover, adriamycin has been shown to decrease nitric oxide (NO) 
formation and thus lead to endothelial dysfunction [168,169]. It has been further shown that, 
in adriamycin-induced nephrotic syndrome, vascular adriamycin exposure and nephrosis 
affect vascular function [170]. Adriamycin exposure reduces endothelium-dependent 
vasodilation, most likely due to impaired stimulated NO release without further impairment 
by nephrosis. Nephrosis, on the other hand, is associated with a reduced basal NO release—
without an additional effect of vascular adriamycin exposure—leading to impairment of the 
normal vascular modulation of vasoconstrictor stimuli. This modulation is an important 
vascular defense mechanism [170] and its impairment might well be involved in the high 
cardiovascular morbidity in proteinuric patients. 
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The anatomical MRI data generated 24 h after SPIO administration (Figures 52 and 53A) 
suggested macrophage infiltration into the kidneys of adriamycin-challenged rats. The signal 
changes detected in vivo correlated well with histological analyses of macrophage infiltration 
(Figure 53E-F). These results are consistent with data from the literature demonstrating that 
adriamycin induces monocyte/macrophage infiltration in glomeruli and in the interstitium 
[171,172]. Also using SPIO administration, we’ve shown before that detection of macrophage 
infiltration by MRI can serve as an earlier marker of chronic rejection in models of kidney 
transplantation [152,153]. 
It has been demonstrated earlier that 1D11, in particular in combination with angiotensin II 
blockade, had antifibrotic effects in models of glomerulonephritis [42,145,146]. In those 
studies, the antibody was administered preventatively, before onset on injury. In the present 
work, the fact that 1D11 was given therapeutically, i.e. antibody treatment started after injury 
onset, may have been one of the reasons for its lack of efficacy. Benigni et al. [173] showed in 
a rat model of nephropathy that beneficial effects of TGF-β antagonism depend on when 
treatment is started. Early treatment with 1D11 was effective; however, a combined 
treatment with an angiotensin-converting enzyme inhibitor was necessary to tackle renal 
damage in the phase of advanced disease. Some of our data suggesting that therapeutic 
treatment with 1D11 even worsened the renal injury induced by adriamycin are in agreement 
with observations in the literature showing that blockade of TGF-β using 1D11 significantly 
impaired the protective effect of regulatory T cells (Treg) in adriamycin-induced kidney injury 
in mice [174]. Infiltration of macrophages, an important component of innate immunity, is 
one of the most striking and constant features of chronic renal injury, and the degree of 
mononuclear cell infiltrate is predictive of subsequent disease progression [175]. 
Macrophages can contribute extensively to tissue damage and progressive renal failure via a 
number of mechanisms, including their production of proinflammatory cytokines and via their 
T cell–stimulatory capacity [176,177]. It has been shown that CD4+CD25+ Treg can 
downregulate the effector phenotype of macrophages and inhibit their production of 
cytokines in a TGF-β-dependent manner, thereby hampering the innate effector function of 
these cells [174,178-180]. Thus, TGF-β, which is accepted as a key mediator of renal fibrosis, 
can protect against renal injury via Treg [45,174]. Our data are also consistent with a study by 
Mesnard et al. [181] showing that 1D11-treated wildtype mice demonstrated higher 
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proteinuria and more pronounced tubular injury in comparison to animals receiving an 
irrelevant matched isotype antibody, as well as with the fact that anti-TGF-β therapy could not 
reverse the degree of glomerular injury in male rats with preexisting renal injury [182]. 
Moreover, modulation of NO can exacerbate tubulointerstitial inflammation in proteinuric 
rats [183]. 
In summary, the data presented here demonstrate the usefulness of MRI in providing 
longitudinal functional and cellular information in a rat model of nephropathy. The DCE MRI 
data were shown to be significantly more sensitive than conventional assessment of GFR 
based on the biochemical analyses of blood and urine to reveal abnormalities in kidney 
function induced by the antibiotic. Anatomical imaging 24 h following SPIO administration 
detected contrast changes that were significantly and inversely correlated with the infiltration 
of macrophages. Both functional and cellular data can support in vivo pharmacological testing 
in the model [184-186]. Moreover, the MRI techniques have translational potential for 
compound testing in humans as the contrast agents adopted are approved for clinical use. Of 
course, care needs to be taken as safety concerns for Gd-based contrast agents have been 
raised, in particular in the context of nephrogenic systemic fibrosis [187,188], a highly 
debilitating scleroderma-like disease occurring in patients with severe or end-stage renal 
failure. The use of macrocyclic Gd-chelates (such as Gd-DOTA) as contrast agent for DCE-MRI 
examinations, since they are safer and more stable when compared to linear open-chain 
agents [189,190], and the restriction to examining patients with GFR values > 30 ml/min/1.73 
m2 [191,192], would for instance be precautions when trying to adopt this approach to 
pharmacological tests in the clinics. 
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7) Overall Discussion and Conclusions 
7.1) Discussion 
The studies performed in this thesis focused on three pillars of preclinical pharmaceutical 
research in the context of lung and kidney fibrosis: the availability of appropriate animal 
models, the availability of readouts or parameters that quantitatively reflect disease evolution 
in those models, and the availability of reference compounds, known to interfere with the 
disease development. To date no pharmacological treatment is available for lung fibrosis, a 
lethal disease characterized by tissue deposition and reduced organ function, or renal fibrosis, 
characterized by glomerulosclerosis, sclerotic tubuli, and tubulointerstitial inflammation. 
Thus, strengthening of the three mentioned pillars will support the preclinical research on 
therapeutics against the two crippling diseases.  
Contribution to the availability of appropriate animal models for pulmonary and renal 
fibrosis 
Oropharyngeal aspiration of bleomycin led to a strong improvement of the in vivo model 
Single [33-35] or multiple [36] IT or IN instillation of bleomycin is commonly used to induce 
experimental pulmonary fibrosis in small rodents. In Chapter 4.1 (“Administration of 
Bleomycin via the Oropharyngeal Aspiration Route Leads to Sustained Lung Fibrosis in Mice 
and Rats as Quantified by UTE-MRI and Histology”) it was shown that OA of bleomycin in mice, 
compared to IN administration, led to a stronger fibrotic response and to pulmonary fibrosis 
that was localized also in the lung periphery and not only around the main airways. These data 
resulted in an improvement of the animal model. The dose of bleomycin could be strongly 
reduced by a factor of 2.5 compared to the IN route of administration, leading to a significantly 
lower bodyweight loss of bleomycin treated animals. Of importance, a refinement of the 
model in the sense of the 3R concept was thus achieved. The shift of the fibrotic foci from the 
main airways more to the periphery makes the model more comparable to the human disease, 
which is an important point for preclinical compound studies and validation of methods and 
readouts that might be applied to humans in a later phase. 
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Adriamycin induced nephropathy as a model for kidney fibrosis 
In Chapter 6.1 (“Adriamycin-Induced Nephropathy in Rats: Functional and Cellular Effects 
Characterized by MRI”) it was shown that i.v. administered adriamycin in rats lead to renal 
fibrosis including pathological changes as glomerulopathy, sclerotic tubules with atrophy of 
the epithelial cells and distended tubules, macrophage infiltration into the renal parenchyma, 
and hydroxyproline deposition, as well as functional changes as reduced glomerular filtration 
rate, perfusion, and renal clearance.  Although adriamycin was already known to induce 
nephropathy in small rodents, the presented data, especially the in vivo MRI readouts, 
delivered further relevant information about the model. The availability of an appropriate and 
well understood animal model for renal fibrosis is of importance for pharmaceutical research, 
since there is still a lack of therapeutic drugs against the disease leading to organ failure that 
often requires its replacement. The adriamycin model in rats may certainly support the 
preclinical research on anti-fibrotic drugs. 
Contribution to the availability of readouts or parameters that quantitatively reflect 
disease evolution  
UTE-MRI reduced acquisition time for imaging the lungs of bleomycin-challenged mice and 
rats  
It has been shown in our laboratories that MRI can non-invasively follow the course of lung 
injury induced by administration of bleomycin to mice [70] and rats [27]. The data of these 
earlier studies were produced applying a GE sequence, which required an acquisition time 
over twenty minutes for imaging the whole lung of a mouse or a rat. For the studies discussed 
in this thesis, except for gated acquisitions, UTE sequences have been used to investigate lung 
volume and bleomycin-induced lung lesions. Due to a reduction of the echo time and a 
decrease in the number of averages, the acquisition times could be significantly shortened as 
compared to previous work [70,72]. Only four minutes were needed to generate images 
covering the whole lung of a mouse. The acquisition time for rat lung imaging could be reduced 
to about seven minutes using 2D UTE and eleven minutes using 3D UTE. This reduction of 
acquisition time means an improvement for pharmaceutical research. With only 4 min 
acquisition time per animal, high-throughput imaging becomes feasible, which is of relevance 
since in vivo studies often include up to 50 animals.  
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A reduced acquisition time means also a shorter anesthesia time. Although MRI is a 
noninvasive tool, anesthesia imposes some stress on the animals. Thus, a reduction of time in 
narcosis certainly supports the 3R concept in the sense of refinement. 
Modulation of MRI signals by hyaluronidase 
Although MRI has been shown to detect bleomycin-induced lung injuries in the lung fibrosis 
model, with significant correlations to post-mortem collagen analyses (histology of picrosirius 
staining and hydroxyproline), additional effort was made to investigate the nature of the 
detected signals. The work in Chapter 4.2 (“MRI-detected, bleomycin-induced lung injuries in 
mice and rats: What is causing the observed changes in MRI signal?”) focused on the origin of 
these MRI signals and investigated the role of hyaluronic acid (HA) in ongoing fibrotic 
processes. The fact that bleomycin-induced MRI-signals could be modulated by hyaluronidase 
(HYAL) support the hypothesis that proteoglycans as HA, through their ability to attract water, 
contributed to the detected MRI-signals. Since HA has been shown to be involved in fibrotic 
processes [109,110] and co-localizes with parts of the extracellular matrix (ECM) [101], the 
data strengthen the detection of BLM-induced injuries by MRI as a noninvasive in vivo readout 
for PF. 
Total Lung Volume as a new readout for lung fibrosis? 
During the past, the amount of lung collagen and related parts of the ECM, as hydroxyproline, 
were in the focus for the post-mortem detection of pulmonary fibrosis. Another way of 
monitoring the course of the disease in vivo, was the assessment of lung function and 
mechanics: Tissue resistance and elastance, as well as decreased compliance have been 
shown in humans [2,15] and in small rodent pulmonary fibrosis models [23-25,28-31].  
Moreover, changes in tidal volume and breathing cycle times have been shown in a mouse 
fibrosis model [113]. In this thesis MRI-detected lung volume was shown to be a non-invasive 
readout for tissue deposition in the rat bleomycin model for pulmonary fibrosis. Tissue 
deposition (of e.g. collagen, elastin and proteoglycans) induced by bleomycin in the lung leads 
to an increase in lung resistance [23,24,26,111,112] and thus to a decrease in lung compliance. 
Therefore, MRI-detected alterations in lung volume might also be considered as reflecting 
changes of lung function in the model.  As therapies aim primarily at improving the lung 
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function, incorporation of this readout into pharmacological testing in the bleomycin model is 
of interest. 
Visualization of renal perfusion, clearance, and macrophage infiltration in the rat adriamycin 
model 
In Chapter 6.1 (“Adriamycin-Induced Nephropathy in Rats: Functional and Cellular Effects 
Characterized by MRI”), MRI was shown to detect nephropathy in the rat adriamycin model. 
Renal clearance was visualized by the i.v. administration of Gd-DOTA and the detection of 
signal changes by GE-MRI, based on the fact that Gd-DOTA decreases the T1 of protons and is 
excreted through the kidneys [147-149]. Tracer washout rate was determined from the Gd-
DOTA concentrations, that were obtained in a time-resolved manner from the induced signal 
changes, and found to be significantly reduced at all time points after adriamycin injection.  
Kidney perfusion was investigated using an i.v. injection of SPIO particles that induced, by a 
change of the local magnetic field (T2* effect), a decrease of MRI signal and was found to be 
reduced six weeks after adriamycin-challenge. Twenty-four hours after SPIO injection, 
anatomical images have been acquired. MRI signal was decreased in adriamycin-treated rats 
four and six weeks after challenge, with a high correlation to the presence of iron loaded 
macrophages in the kidney, thus suggesting that MRI was able to visualize macrophage 
infiltration in the rat adriamycin model. 
The three in vivo MRI readouts, visualization of macrophage infiltration, renal clearance, and 
kidney perfusion, are shown in this thesis to be valuable tools to monitor nephropathy in vivo. 
The DCE MRI data were shown to be significantly more sensitive than conventional 
assessment of GFR based on the biochemical analyses of blood and urine to reveal 
abnormalities in kidney function induced by the antibiotic. In combination with the adriamycin 
model, these MRI techniques may have a high impact on the development of compounds 
against renal fibrosis. Moreover, the MRI techniques have translational potential for 
compound testing in humans as the contrast agents adopted are approved for clinical use.  
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Contributions to pharmacology 
1D11 showed no therapeutic on adriamycin-induced nephropathy 
The TGF-β antibody, 1D11, in particular in combination with angiotensin II blockade, showed 
antifibrotic effects in models of glomerulonephritis [42,145,146]. In those studies, the 
antibody was administered preventatively, before onset of injury, while in this thesis the 
therapeutic effect of the antibody was investigated. As described in Chapter 6.1 (“Adriamycin-
Induced Nephropathy in Rats: Functional and Cellular Effects Characterized by MRI”), 1D11 
was administered after the induction of nephropathy by injection of adriamycin. None of the 
assessed readouts showed a therapeutic effect of 1D11 on adriamycin-induced nephropathy. 
Of note, some of the readouts suggested that therapeutic treatment with 1D11 even 
worsened the renal injury induced by adriamycin, which is in agreement with data in the 
literature showing that blockade of TGF-β using 1D11 significantly impaired the protective 
effect of regulatory T cells (Treg) in adriamycin-induced kidney injury in mice [174]. The MRI-
detected influence of 1D11 on kidney perfusion and TWR were consistent with the 
histologically observed increase of glomerulopathy. Thus, when administered therapeutically, 
1D11 may not serve as a reference compound for the preclinical research on renal fibrosis, 
but in the discussed study it confirmed MRI as an in vivo readout for adriamycin induced 
nephropathy. 
PT100 showed an anti-fibro-proliferative effect in the mouse bleomycin model 
As discussed in Chapter 5.1 (“Therapeutic Effects of the Fibroblast Activation Protein Inhibitor, 
PT100, in a Murine Model of Pulmonary Fibrosis”), effects of talabostat (PT100) in the lungs 
of bleomycin-challenged C57BL/6 mice were assessed longitudinally with proton MRI and 
compared to post-mortem analyses. The lesions induced by bleomycin and detected by UTE-
MRI in the lungs of vehicle-treated mice progressed over time. In contrast, the responses 
elicited by BLM did not progress in animals receiving PT100. Histology at the end of the study 
demonstrated significant less fibrosis in PT100- than in vehicle-treated, BLM-challenged mice. 
These observations suggest that the compound administered therapeutically had an anti-
fibro-proliferative effect. Of note, treatment with PT100 was started one day after the last 
bleomycin administration, a time point when substantial fibrosis was already present. 
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Although PT100 showed an anti-fibro-proliferative effect and stopped lesion progression, the 
MRI data showed that the compound was not able to reduce lung injuries that were induced 
during the first six day of bleomycin-challenge. Further studies should be performed by 
shifting the beginning of treatment to a later time point after last bleomycin administration.  
Pasireotide reduced bleomycin-induced lung injuries in rats 
Pasireotide (SOM230), a somatostatin analogue, binds to four out of five sst receptors (sst1, 
sst2A, sst3, and sst5) which have been reported to be upregulated in human fibrotic lungs 
[135] and in the mouse bleoymycin model [136].  As described in Chapter 5.2 (“Therapeutic 
Effects of Pasireotide on Bleomycin-Induced Lung Injuries in Rats - Detection by MRI and post-
mortem analysis”), the long acting release (LAR) form of SOM230 was tested in a rat model of 
pulmonary fibrosis adopting a therapeutic experimental setting. SOM230 reduced bleomycin-
induced lung lesions, which could be detected by 3D-UTE MRI. Twelve days after treatment 
begin no difference in MRI signal volume, total lung volume, and lung wet and dry weight 
could be observed between values for SOM230-treated, bleomycin-challenged rats and those 
for saline-challenged animals. The hydroxyproline content was slightly reduced for SOM230- 
compared to vehicle-treated, bleomycin-challenged rats. Based on the work exposed in 
Chapter 4.3 (“MRI-detected lung volume as a noninvasive readout for tissue deposition in the 
rat bleomycin model of pulmonary fibrosis”), the fact that total lung volumes as well as wet, 
and dry lung weights were comparable for saline-challenged animals and for SOM230-treated, 
bleomycin-challenged rats indicated an effect of SOM230 on lung function, since tissue 
deposition is related to lung elastance and compliance. All these data suggested that SOM230 
had a therapeutic effect on bleomycin-induced pulmonary fibrosis. Although further results, 
as histology, RT-PCR, and blood sample analyses have to confirm these observations, the 
presented work strongly recommends SOM230 as a reference compound for MRI studies on 
pulmonary fibrosis. To our knowledge this is the first report that bleomycin-induced, MRI-
detected lung injuries can be reduced by a compound in a model of established fibrosis.  
7.2) Conclusion 
The introduction of oropharyngeal aspiration of bleomycin for the induction of pulmonary 
fibrosis in small rodents and the confirmation of adriamycin-induced nephropathy as a model 
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of renal fibrosis strengthened the two models for pulmonary and renal fibrosis as tools for 
preclinical research. 
Further improvements, regarding MRI as a non-invasive in vivo readout for pulmonary and 
renal fibrosis, were reached (i) by adopting UTE MRI for lung imaging, i.e., in the detection and 
quantification of lesions elicited by bleomycin in the lungs of mice and rats and in the 
evaluation of total lung volume as a readout for tissue deposition in the rat bleomycin model 
and (ii) by validating MRI techniques for the detection and quantification of renal function and 
macrophage infiltration in the adriamycin model of kidney injury in rats.  
Additionally, two reference compounds, PT100 and SOM230, were found. This is of particular 
importance considering the fact that no appropriate reference compounds exist for 
experimental research in lung fibrosis. Therefore, PT100 and SOM230 may become very useful 
when testing further therapies for pulmonary fibrosis in small rodents. 
Concluding, it can be said that the studies discussed in this thesis deliver contributions to all 
three pillars of preclinical pharmaceutical research: the availability of appropriate animal 
models, the availability of readouts or parameters that quantitatively reflect disease evolution 
in those models, and the availability of reference compounds, known to interfere with the 
disease development. Therefore, we hope that the studies summarized here will have an 
impact on preclinical research concerning pulmonary and kidney fibrosis in small rodents. 
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